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SUMMARY
There has been much interest focusing on the contribution of cytokines to the genetic 
variation known to occur between the immune responses of different individuals. 
Interleukin-6 (IL-6), originally defined as a B cell growth factor, was rapidly identified 
as under-pinning the induction of the acute-phase response and being heavily involved 
in inflammatory responses generally. More recently, the role of IL-6 in human 
malignancy has become a topic of interest. The aim of this study was to examine four 
polymorphic elements, three in the promoter 5’region and one VNTR in the 3’region 
and define the relationships of these alleles in a West of Scotland control population. 
The relationships were then observed in two malignant cohorts; patients diagnosed with 
Gastric carcinoma and patients diagnosed with Barrett’s Oesophagus, to determine 
possible disease related associations. Investigation of an African American cohort and 
subsequent rheumatoid individuals also provided a comparison in a different ethnic 
group and the associations of the polymorphic elements in an autoimmune disease. 
Digestion of amplified DNA determined the polymorphisms in the 5’ promoter region 
and PAGE separation resolved the minisatellite alleles at the 3 ’ VNTR. The data 
revealed that strong significant associations between the alleles form three prominent 5’ 
promoter haplotype families and four dominant extended haplotypes, which include the 
3’VNTR in the West-of-Scotland population. In the gastric carcinoma cohort the 4 
polymorphisms were similarly distributed to the control population and did not prove to 
be genetic markers relating to this disease. Similarly no statistical significance was 
detected with the Barrett’s Oesophagus cohort. However, the presence of H.pylori in the 
malignant cohorts proved to be of significant importance in the distribution the 5’ 
haplotype families. The haplotype IL6.01 was significantly more prominent in H.Pylori 
positive patients of the gastric cohort, where as the haplotype IL6.02 was more 
prominent in the Barrett’s Oesophagus patients. In the African American population, no 
statistical difference was detected between the control cohort and the Rheumatoid 
arthritis patients. The results reported here demonstrate that markers cannot necessarily 
be considered independent of one another across human cytokine genes. Additionally, 
where markers fall in, or close to, functional elements such as transcription factor 
binding sites, it should be remembered that other polymorphic elements might be 
contributing to the observed effect.
X
INTRODUCTION
CHAPTER 1
Cytokines are small soluble proteins made by many cell types that are produced to 
regulate immune and inflammatory responses and mediate cell growth, differentiation 
and repair. In general, cytokines are synthesised in response to inflammatory or 
antigenic stimuli and their action is initiated by binding to specific receptors on the 
target cells altering their RNA and protein synthesis. Cytokine secretion is usually a 
self-limiting event due to production regulated by the AU rich sequences in the 3’ 
untranslated regions, which render most cytokine mRNAs unstable. Cytokines have 
multiple different effects on a variety of cell types, which results in considerable 
overlapping and redundancy between them.
According to their principle actions, cytokines can be organised into three groups. The 
first mediates and regulate specific immunity and are produced by T-lymphocytes in 
response to specific antigen recognition. The second are collectively called colony- 
stimulating factors and stimulate the growth of bone-marrow progenitors. The final 
group mediates innate immune mechanisms and includes antiviral, pro-inflammatory 
and regulatory cytokines [Abbas et al, Roitt,].
Recently there has been much interest focusing on the contribution of cytokines to the 
genetic variation known to occur between the immune responses of different 
individuals. While the majority of work has been carried out on the TNF locus, other 
cytokines have featured such as IL-1 and IL-10. More recently Interleukin-6 and its 
role in human disease has been studied.
1. INTERLEUKIN-6
Interleukin-6 is a multifunctional cytokine with a wide spectrum of biological activities. 
This diversity created considerable confusion during identification and thus this protein 
was previously known by terms that reflected the characteristics identified in the 
studies. There were three main lines of investigation running in parallel, which 
eventually led to the conclusion that they were all the same molecule.
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The original discovery of interleukin- 6 was in 1980 by Weissenbach et al who isolated 
two cDNA clones from human fibroblasts stimulated for Interferon-p (IFN-P) 
expression. One clone coded for IFN-P and the second for a protein of molecular weight 
23-26 kilodaltons. This clone was termed "IFN-P2". However, Content and co-workers 
[Content et al, 1982] renamed this protein as "26kD factor" or "26kD protein" after 
observing that it lacked antiviral activity. Further investigation detected different 
transcriptional regulation [Poupart et al, 1984] and sequencing in 1986 [Haegermann et 
al, 1986] confirmed lack of structural homology with IFN-p. Although investigations 
suggested that this protein played an intermediary role in inflammation or 
immunoregulatory processes by detecting its induction by a leukocyte-derived factor 
belonging to the IL-1 family [Content et al, 1985], the physiological functions remained 
ambiguous at this point.
Meanwhile a "B-cell differentiating factor" (initially called "B-BCDF") was isolated 
and purified from a human B-lymphoblastoid cell line [Yoshizaki et al, 1984], which 
was later renamed "B-cell stimulating factor 2" (BSF-2) when it was observed to induce 
the final maturation of B-cells into immunoglobulin-secreting cells. Purification to 
homogeneity [Hirano et al, 1985] and cloning from a human T-cell leukaemia virus 
[Shimizu et al, 1985] led to sequencing [Hirano et al, 1986] that later showed identity to 
IFN-p2 [Sehgal et al, 1987].
The final area of investigation concentrated on growth factors. "Interleukin hybridoma 
plasmacytoma 1" (IL-HP1) was purified from the supernatant of a murine helper T cell 
(Van Snick et al, 1987) and a similar molecule from a macrophage supernatant termed 
"plasmacytoma growth factor" (PCT-GF) [Nordan and Potter, 1986]. This led to the 
purification of a human "hybridoma/plasmacytoma growth factor" (HPGF) from an 
osteosarcoma cell line treated with IL-1 [Van Damme et al, 1987], which showed 
identical amino acid terminal sequence to that predicted from the 26Kd cDNA clone. 
Additionally, a "fibrinogen stimulating factor" detected by Ritchie and co workers, 
which was later renamed "Hepatocyte stimulating factor" (HSF), was observed to share 
immunological and functional identity to IFN-P2 [Gauldie et al, 1987].
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The realisation that all these molecules were the same cytokine led to the proposal that 
it should be renamed "Interleukin-6" to avoid further confusion over nomenclature 
[Poupart et al, 1987, Gauldie et al, 1987]. The various nomenclatures relating to IL-6 
are summarised in Table 1.
IL-6 production is secreted by a large number of cell types, including monocytes and 
macrophages [Aarden et al, 1987], fibroblasts [Weissenbach et al, 1980], endothelial 
cells [Jirik et al, 1989], keratinocytes [Grossman et al, 1989], T cells [Garman et al,
1987], synoviocytes [Gueme et al, 1989], and pancreatic cells [Campbell et al, 1989]. 
These cells do not constitutively produce IL-6, but instead it is induced and regulated by 
a number of stimuli, the most common of which are LPS, IL-1 and TNF-a. Yet IL-6 has 
also been observed to inhibit the production of both TNF-a and IL-1 in order to 
attenuate the inflammatory response caused by the primary stimulus. Therefore these 
substances can be seen to create a cytokine cascade but with a regulatory feedback loop.
1.2. ILz^SJRUCTJJRE
The human IL-6 gene has been localised to chromosome 7p21 [Bowcock et al, 1988] 
and consists of 5 exons and 4 introns. [Yasukawa et al, 1987]. Its organisation is 
homologous to that of granulocyte colony stimulating factor (G-CSF), suggesting that 
these genes have evolved from a common ancestral gene [Hirano et al, 1986]. 
Additionally, a high degree of similarity has been described between human IL-6 cDNA 
and murine IL-6 at both nucleotide and amino acid sequences, with 65% and 42% 
homology respectively [Tanabe et al, 1988]. IL-6 codes for a protein of 184 amino 
acids, which includes 2 potential N-glycosylation sites and 4 cysteine residues and is 
formed by the cleavage of a 28aa signal peptide from a 212aa precursor protein [Hirano 
et al, 1986].
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TABLE 1 
Alternative synonyms for Interleukin-6 (IL-6)
N am e A uthor
iFN-p2 Weissenbach et al, 1980
FSF Ritchie et al, 1983
26k Content et al, 1982
HSF Ritchie et al, 1983
B-BCDF/BCDF Yoshizaki et al, 1984
BSF-2 Hirano et al, 1985
IL-HP1 Van Snick et al, 1986
PCT-GF Nordan and Potter, 1986
HPGF Van Damme et al, 1987
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Due to extensive post-translational modifications, natural human IL-6 exists in a 
number of different forms with molecular weights ranging form 21K-30K [Hirano et al, 
1986, May et al, 1988]. Both monocytes and fibroblasts have shown to secrete at least 5 
different isoforms although the higher forms are absent when the cells are inhibited by 
tunicamycin, suggesting that these forms are N-glycosylated [Bauer et al, 1988, May et 
al, 1988]. Yet a preferential shift in the secretion of these 29KDa triplets can be 
obtained by partially inhibiting the cellular protein synthesis, observed by the inclusion 
of cyclohexamide [May et al, 1988]. This suggests that the multiple forms of IL-6 are 
actively regulated. Additional post-translation modifications have been observed, such 
as sulphation and phosphorylation at serine residues in specific tissues. However these 
appear to have no significant effect on the biological activity of IL-6 [Simpson et al,
1997].
1.3. IL-6 RECEPTOR AND SIGNAL TRANSDUCTION
The human IL-6 receptor is an 80KDa glycoprotein consisting of 468 amino acids 
including a 19aa signal peptide, a 28aa transmembrane domain and six potential 
glycosylation sites [Yamasaki et al, 1988]. The first domain in the extracellular region 
consists of 90aa which is homologous to the immunoglobulin (Ig) superfamily 
[Yamasaki et al, 1988] followed by a cytokine binding domain (CBD) consisting of two 
fibronectin type III- like domains (FN-III) (Simpson et al, 1997). The CBD is 
characteristic of the class I cytokine receptor family which includes interleukins-2 to -9, 
IL-11, IL-13, Leukaemia Inhibitory Factor (LIF), Erythropoietin (Epo), Ciliary 
neurotrophic factor (CNTF), growth hormone (GH) and prolactin [Thoreau et al, 1991, 
Kishimoto et al, 1994].
There is also a short cytoplasmic segment of 82aa that, unlike other growth factor 
receptors, lacks tyrosine kinase domains [Yamasaki et al, 1988]. This region however is 
not essential for signal transduction and neither is the transmembrane domain [Taga et 
al, 1989].
The IL-6 receptor can also exist in soluble form (sIL-6R) and has been detected in 
normal human urine and serum [Novick et al, 1989, Narazaki et al, 1993]. Its 
physiological role however is not yet well understood.
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For IL-6 transduction, a signal transducer (termed gpl30) is required to bind to the IL- 
6-IL-6R binary complex to form the high affinity ternary complex IL-6~IL-6R--gpl30 
[Taga et al, 1989]. The cDNA of the human gpl30 encodes for a 918aa protein, 
including a 22aa signal peptide, an extracellular region of 527aa, a transmembrane 
domain of 22aa and a cytoplasmic domain of 277aa [Hibi et al, 1990]. This protein of 
mature molecular weight lOlKDa also has 14 potential glycosylation sites. The 
cytoplasmic domain of gpl30 has no intrinsic catalytic activity [Hibi et al, 1990]. A 
segment of ~200aa in the extracellular region possesses typical features of this cytokine 
family. Additionally this region comprises of six units of fibronectin type III modules 
and shows closest similarity to the G-CSF receptor than to any of the other family 
members [Hibi et al, 1990].
Transcriptional activation studies have demonstrated that there are two signaling 
pathways mediating the IL-6 effects. The binding of IL-6 to IL-6R results in the 
homodimerisation of gpl30 and activation of the tyrosine kinases of the JAK family 
(Janus Kinase), which then phosphorylate the STAT family transcription factors (signal 
transducers and activators of transcription) [Darnell et al, 1994]. The second pathway 
involves the G-protein Ras and Raf, which activate the MAPK’s (mitogen activating 
protein kinases) [Gadient 1997].
1.4. BIOLOGICAL ACTIVITIES
IL-6 has a wide range of biological activities, which, as previously discussed, led to the 
long list of synonyms. These activities include pro-inflammatory responses such as T- 
cell activation, B-cell differentiation, acute phase response, as well as some anti­
inflammatory activities.
B-cell differentiation
One of the earliest descriptions of IL-6 activity was as a role in B-cell differentiation. 
IL-6 was shown to induce immunoglobulin (Ig) production in stimulated 
Staphylococcus aureus Cowan strain I and Epstein Barr virus (EBV) transformed cell 
lines without inducing B-cell growth [Hirano et al, 1985]. Further study confirmed the 
importance of IL-6 to immunoglobulin production by observing the strong inhibition of 
Ig production in mononuclear cells stimulated by pokeweed mitogen when treated with
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anti-IL-6 antibody [Muraguchi et al, 1988]. The strong effect of IL-6 was observed even 
when added on the fourth day of an eight-day culture suggesting that IL-6 acted late in 
the response. IL-6 activity was also demonstrated when it was identified in the 
supernatant of LPS-activated monocytes [Tosato et al, 1988]. The addition of these 
fluids to EBV-infected human B-cells enhanced its production 30-50 fold.
IL-6 has also been shown to augment antigen specific antibody synthesis in primary and 
anmnestic responses both in vitro and in vivo [Takatsuki et al, 1988]. The inhibition of 
IL-6 by anti-IL-6 antibody confirmed this cytokine as the enhancing agent.
Furthermore, IL-6 was enhanced the primary and secondary antibody responses, in mice 
with a stronger effect observed in the secondary response.
B-cell hybridoma and plasmacytoma activity
An activity related to B-cell differentiation is the ability of IL-6 to promote hybridoma 
and plasmacytoma growth [Aarden et al, 1987, Nordan and Potter, 1986, Van Damme 
et al, 1987]. IL-6 was shown to be required for the proliferation of newly formed B-cell 
hybridomas in pristane-treated mice [Bazin and Lemieux, 1987], whereby IL-6 
sensitive cells induced the formation of ascetic tumours. Furthermore, IL-6 was 
required for the survival of newly formed B-cell hybridomas as its absence eventually 
led to tumour cell death. The role of IL-6 in plasmacytoma growth was observed by 
Suematsu et al [1989] in IL-6 transgenic mice. All the mice showed plasmacytoses 
expressing high IL-6 concentrations and polyclonal IgGl. The plasma cells were shown 
to have infiltrated into the lungs, liver and kidney, yet upon transplantation could not 
induce plasmacytomas. This study therefore indicated that IL-6 could induce polyclonal 
plasmacytosis, but not plasmacytoma.
T-cell
The involvement of IL-6 with T-cells was first detected whilst searching for new factors 
involved in T-cell activation. IL-6 was induced proliferation of purified peripheral 
murine T-lymphocytes in the presence of lectins [Garman et al, 1987] and thus act as a 
second signal for production of IL-2. IL-6 has since been shown to be also involved in 
the differentiation of cytolytic T-cells. Takai et al [1988] observed that three cytokines 
were involved in differentiation of Ly2+ CTL differentiation, one being IL-6.
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Further studies on cytotoxic T-cell (CTL) differentiation have used recombinant IL-6 
[Okada et al, 1988]. Recombinant IL-6 (rIL-6) alone was unable to induce CTL in 
cocultures of human T-cells stimulated by allogeneic leukocytes. It was observed that 
rIL-2 was required as well during the early phase of induction. Yet the activity of IL-6 
was not mediated by the induction of IL-2 production, as anti-IL-2 antibody had no 
effect on IL-6. Furthermore the ability of rIL-6 to generate CTL when added 72 hours 
after culture initiation suggested a role as a late acting differentiation factor.
Haematopoiesis
IL-6 has three main roles in haematopoiesis; in progenitor cell expression, in 
megakaryocyte differentiation and in myelopoiesis.
Studies in IL-3 dependent haematopoietic progenitor cells have shown that combination 
with IL-6 decreases the time that dormant cells reside in GO phase thus increasing the 
speed of colony appearance [Ikebuchi et al, 1987]. IL-6 was also able to synergise with 
GM-CSF and M-CSF [Hoang et al, 1988, Bot et al, 1989] although the synergy with M- 
CSF was only observed in highly purified progenitor cells [Bot et al, 1989]. 
Furthermore, early addition of IL-6 was required to produce an enhancing effect.
Studies have also suggested that IL-6 has a significant effect on megakaryocyte 
development. In the presence of IL-3, the addition of IL-6 directly augmented the 
maturation of murine megakaryocytes defined by size increments, Acetylcholinesterase 
activity and ploidy. The absence of IL-3 produced no detectable effect. In vivo, 
increased numbers of megakaryocytes in bone marrow were observed in transgenic 
mice [Suematsu et al, 1989].
Early studies implicating the ability of IL-6 to influence myelopoiesis was observed by 
Chen et al [1988]. IL-6 induced the terminal differentiation of the myeloleukemic Ml 
cells into growth arrested macrophage-like cells and partial differentiation of histocytic 
lymphoma U937cells. Further studies indicating IL-6 stimulating myelopoiesis were 
confirmed in vivo where by myeloid hyperplasia was observed in rats 12 hours after 
administration of rIL-6 [Ulich et al, 1989].
Acute phase response
The acute phase response is the change in the transcription of certain hepatic proteins in 
response to inflammation. When this response was induced by LPS, IL-1 or TNFa, the 
cytokine IL-6 was shown to act as the mediator [Geiger et al, 1988]. The importance of 
IL-6 in acute phase response was further confirmed in vivo [Marikovic et al, 1989, 
Geiger et al, 1988b]. Recombinant IL-6 combined with glucocorticoids injected into 
rats induced the mRNA for the major rat acute phase proteins a 2-macroglobulin, 
fibrinogen thiostatin and hemopexin. Hattori et al [1990] observed the effect to be due 
to the formation of a complex between the IL-6 response element of the genes and the 
hepatic nuclear proteins. Furthermore IL-6 has been observed to stimulate the full 
spectrum of acute phase proteins in adult human hepatocytes, i.e. C-reactive protein, 
serum amyloid A, fibrinogen, a 1-antichymotrypsin and haptoglobin [Castell et al,
1989]. The association between serum IL-6 levels in severely burned patients and C- 
reactive protein further supports a role for IL-6 in the acute phase response.
Nervous system
There has been much evidence indicating that IL-6 has an essential effect on the 
neurons in the peripheral and central nervous system. IL-6 was first described to have 
neuroprotective actions on CNS neuronal subpopulations by Hama et al [1989]. The 
survival of cholinergic neurons and catecholaminergic neurons in the basal forebrain 
and mesencephalon respectively was supported by IL-6. Additionally, IL-6 can induce 
neuronal differentiation of PC 12 cells (a rat adrenal pheochromocytoma) into neuronal 
cells, an activity similar to the differentiation process observed by the nerve growth 
factor [Satoh et al, 1988].
In addition to neuronal effects, IL-6 has been observed to induce astrocyte proliferation 
in vitro [Selmaj et al, 1990], suggesting that increased levels of IL-6 may have an effect 
in astrogliosis. Additionally, IL-6 can stimulate nerve growth factor synthesis in 
cultured astrocytes [Frei et al, 1989].
Bone metabolism
IL-6 also plays an important role in bone metabolism through induction of osteoclast 
activity [Tamura et al, 1993, Kurihara et al, 1990]. Multinucleated cells (MNC)
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expressing the osteoclast phenotype, adapted from long term human marrow cultures, 
can be stimulated in the presence of mouse IL-6 and sIL-6. Studies have shown that in 
response to the combination of recombinant IL-1 and TNF, IL-6 secretion in osteoblast­
like cells and murine bone-marrow stromal cells increases up to 10,000 fold, yet is 
inhibited by 17p-oestradiol [Girasole et al, 1992]. Furthermore, inhibition of osteoclast 
precursors was detected in oestrogen-depleted mice when treated with anti-IL-6 
monoclonal antibodies. These suggest that the inhibition of IL-6 gene expression by 
oestrogen may partly inhibit osteoclast activation [Jilka et al, 1992]. This was further 
supported in IL-6 deficient mice, which were observed to be protected from bone loss 
associated with ovariectomy [Poli et al, 1994].
Anti-inflammatory activities
IL-6 has a number of properties that lead to inflammation and is essentially a pro- 
inflammatory cytokine. IL-6 can suppress the inflammatory functions mediated by T- 
cells by inhibiting delayed type hypersensitivity and adjuvant arthritis [Mihara et al, 
1991]. Furthermore IL-6 can induce the synthesis of metalloproteinases-1, an inhibitory 
enzyme to the matrix metalloproteases [Lotz and Gueme, 1991]. This suggests that IL-6 
may also have protective mechanisms that balance the catabolic effects of other 
cytokines such as TNFa and IL-1 p.
1.5. THE IL-6 PROMOTER
The 5* flanking region of the human IL-6 gene is a very complex region whose strong 
homology in the first 300bp to murine IL-6 underlines its importance [Tanabe et al,
1988]. The regulatory elements can be observed in Figure. 1. The 5' flanking region of 
the IL-6 gene contains a number of putative cis-acting response elements, which 
mediate the activation of the promoter, including those for AP-1, NF-kB, and the serum 
response element (SRE), which is composed of the cAMP response element (CRE) and 
nuclear factor IL-6 (NF-IL-6). Brach et al [1992] observed NF-kB and NF-IL-6 activity 
during the synthesis of IL-6 in human blood monocytes when induced by LTB4. These 
have since been detected to act as bacterial and mycobacterial response elements when 
stimulated by LPS or Lipoarabinomannan (LAM). This lipid glycoprotein of the 
mycobacterial cell wall was able to induce mononuclear phagocytes to release IL-6 
(Zhang et al, 1994). Transcriptional activation involving NF-kB to inducing IL-6 gene
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expression in mononuclear phagocytes was again observed with recombinant human 
Leukaemia Inhibitory Factor (LIF) [Gruss et al, 1992].
Simultaneous activity of multiple regulatory elements has also been shown to mediate 
IL-6 gene expression. The transcription factors MRE, AP-1, NF-kB and NF-IL6 were 
required for stimulation with cAMP and postglandins as mutations within these 
elements significantly reduced inducibility of IL-6 in monocytic cells [Dendorfer et al, 
1994], suggesting that each of the sites contribute to the expression.
Combinations of trans and cis-acting elements can mediate repression of the IL-6 
promoter, such as the regulatory factor Fos. Nuclear extracts from HeLa cells were 
inhibited by the fos E DNA fragment and c-fos oligonucleotide [Ray et al, 1989], 
Additionally, wild type p53 and retinoblastoma susceptibility gene product have also 
been identified as transcriptional repressors in modulating IL-6 gene expression during 
cellular differentiation and oncogenesis [Santhanam et al, 1991].
Oestrogen has also been recognised to repress expression of IL-6. Using IL-6 promoter 
CAT constructs containing either 1.2kb fragment or a 225bp fragment of the promoter, 
Pottratz et al [1994] observed that 17p-oestradiol had no effect on the activity unless 
these were co-transfected with an hER plasmid. Furthermore, they observed that the 
latter IL-6 promoter plasmid was inhibited by 17p-oestradiol in MBA 13.2, cells which 
constitutively express oestrogen receptor. These results therefore suggested that 17[3- 
oestradiol inhibits IL-6 gene transcriptional activation by an ER-dependent mechanism.
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-570 -172
c-fos SRE homology-392 • -373
GRE, GRE; CRE NF-IL6AnTn AP-1 NF-kB start+1
Tract
Transcription factor Location
GRE, -557 to -552
GRE 2 -466 to -461
AP-1 -283 to -277
CRE -163 to -158
NF-IL6 (C/EBPP) -158 to -145
NF-kB -73 to -64
FIGURE 1. Schematic representation of the 5’ flanking region of the IL-6 gene 
identifying the 3 SNPs and transcription factor binding sites
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1.6. ALLELIC VARIANTS
There have been a number of polymorphic elements observed in the IL-6 gene. A 
polymorphism can be defined as the occurrence of two or more genetically determined 
forms in a frequency of greater than 1%, suggesting that this Mendelian trait could not 
be maintained by mutation alone. The majority of recognised DNA polymorphisms are 
single base-pair changes and is known as single nucleotide polymorphisms (SNPs). 
These are generally detected by an alteration of a restriction enzyme recognition site 
and are therefore also termed as restriction fragment length polymorphisms (RFLPs).
DNA sequence variation can also arise in DNA sequences known as variable number 
tandem repeats (VNTR). These are arrays of short nucleotide sequences dispersed 
throughout the genome that are repeated in a tandem row. This family of repetitive non­
coding DNA sequences can be classified into 3 groups. Satellite sequences, located in 
the heterochromatin arrays of repeats ranging in size from 5 to lOObp and are organised 
in clusters of approximately 100Mb. Microsatellite sequences are approximately lOObp 
long made up of 2-6bp repeats, whilst Minisatellite sequences range from 0.5 to 30kb 
made up of 15-70bp repeats. Both these groups are found in the euchromatin region.
These polymorphic elements can affect the gene in a number of ways. Non-conservative 
mutation within the coding region can produce a change in the protein structure, 
resulting in a functional change of the expressed protein. Conservative mutations 
(silent), which do not alter the amino acid sequence, can influence the protein 
expression by altering the mRNA stability and level of gene transcription. 
Polymorphisms in the 5' promoter and 3 ’ regulatory region of the gene may have the 
most significant effect on transcription. Polymorphisms in the promoter may alter the 
structure of transcription factor binding sites; where as polymorphisms in the 3' 
regulatory site may modulate enhancers and silencers.
There have been 4 single base pair polymorphisms detected in the promoter region of 
IL-6. In 1998, Olomolaiye et al identified a G/C substitution at -172 using the 
restriction enzyme Nla-III. It is postulated that the allele G is ancestral and that the 
allele C represents a relatively recent change in the 5’ sequence. It has since been 
identified in many populations, including Caucasians, Gujarati Indians and Afro-
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Caribbeans [Fishman et al, 1997]. The proximity of the SNP to a glucocorticoid 
receptor site suggested that a base pair substitution might potentially influence the 
binding and hence, its ability to repress transcriptional activation [Ray et al, 1990]. This 
instigated further analysis of the polymorphism and its effect in disease populations and 
identified an association with systemic-Onset Juvenile chronic arthritis [Fishman et al,
1997]. Since these unique findings, this SNP has also been investigated in Systemic 
Lupus Erythematosus (SLE) [Schotte et al, 2001], Alzheimer’s [Bagli et al, 2000] and 
Inflammatory Bowel Disease [Kelin et al, 2001], all of which showed no association.
Bowcock et al [1987] also observed a base pair substitution in the 5’ flanking region 
using the restriction enzyme Bgll. This was observed in a Caucasian and an African 
population. Further analysis showed no disease association with Rheumatoid arthritis, 
SLE or pauci-articular JCA [Fugger et al, 1989]. Similarly, a G/A base pair substitution 
at -594 detected in Caucasians [Faulds et al, Accession number AF048962] has, to date, 
shown no disease association. A fourth base pair substitution has only been recently 
observed by Dr McNicholl and has yet to be published. This is a G/C substitution at -  
570 detected in an African American population.
Polymorphisms have also been observed in the 3’ region of the gene. The restriction 
enzyme MspI identified a base pair substitution within the fifth exon, and has been 
observed in Pygmies, Chinese and Melanesians.
A VNTR has also been detected in IL-6 by Bowcock [1988] Located within lkb of the 
3’flanking region, this AT rich region produces insertions of between 0.07 and 0.23 kb 
during DNA replication. Bowcock identified 4 alleles by using 10 different enzymes, 
although mentioned that more may be present due to unresolvable microheterogeneity 
caused by the low-resolution of agarose gel separation. Recently, Murray et al [1997] 
utilised the ABI machine to observe another two alleles in a Caucasian population and 
further demonstrated an association between genotype for the 3’region and peak bone 
mineral density in women.
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CHAPTER 2
Dysregulation of the body's carefully regulated system often leads to diseases. These 
can be classified into three main types: Infectious, Neoplastic, and Autoimmune 
diseases. Neoplastic diseases are generally caused by over production of cells due to the 
dysregulation of replication, thus producing a tumour. Cells that remain localised 
produce 'Benign tumours', which pose little risk to the body. However abnormal cells 
that are able to spread into alien sites are classed as 'malignant tumours' and can 
potentially be life threatening. In autoimmune diseases, dysregulation of the immune 
system produced by defects in congenital or acquired mediators of immunity can result 
in immunodeficiencies, again possibly resulting in mortality. In the majority of diseases 
there is no exclusive causative factor, but rather a combination of both genetic and 
environmental factors contributing the observed effect.
There have been many studies that have indicated IL-6 to be involved in human 
malignancy and autoimmune diseases. IL-6 production has been noted in a number of 
tumour cell lines including multiple myeloma [Kawano et al, 1988], renal cell 
carcinoma [Miki et al, 1989] ovarian carcinoma (Watson et al, 1990), cervical 
caricinoma [Eustace et al, 1993], lung cancer [Jian et al, 1998], and Kaposi's sarcoma of 
AIDS [Miles et al, 1990], showing its ability to act as an autocrine growth stimulator 
during human melanoma progression. Significantly increased serum levels of IL-6 
production have also been detected in Cholangiocarcinoma [Goydos et al, 1998],
Crohn's disease and ulcerative colitis [Mahida et al 1991, Hyams et al, 1993, Holtkamp 
et al, 1995], and colorectal carcinoma [Kinoshita et al, 1999].
2.1 GASTRIC CANCER
Gastric cancer is characterised as a malignant neoplasm of the stomach mucosa [Wu et 
al, 1997]. Although recent advances have led to early diagnosis and treatment, it still 
remains to be the second most common malignant disease world wide [Everett et al,
1998] with poor prognosis [Morris et al, 1997]. There are two histological types of 
gastric cancer termed ‘Intestinal’ and ‘Diffuse’. The intestinal tumours are associated 
with intestinal metaplasia of the stomach and often ulcerate while the diffuse generally 
lead to a thickening of the stomach lining. The intestinal type is more prevalent in older 
men while the diffuse is more common in women of blood group A. The observation 
that the diffuse type has a hereditary basis suggests that the two histological types
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possess different genetic pathways [Wu et al, 1997]. According to the invasiveness of 
tumour cells, gastric cancer can also be divided into early and advanced stages. 
Adenocarcinoma in early gastric cancer is confined to the mucosa or sub-mucosa and 
detection of cancer in this stage provides patients a high survival rate [Everett et al,
1998].
The transformation of the gastric mucosa and progression of stomach cancer are 
presently incompletely understood. However dietary, environmental and genetic factors 
have a role. Ever since Helicobacter pylori were first discovered in 1982, it has been 
extensively studied in association with gastric cancer. Early supportive evidence linking 
Helicobacter pylori to gastric cancer was provided by Parsonnet et al [1991] who tested 
for the presence of IgG antibodies to this bacterium. In comparison to control subjects, 
patients seropositive for this bacterium were three times more likely to have gastric 
adenocarcinoma in the following 1-24 years, thus suggesting a strong association 
between H. pylori exposure and gastric malignancy. Furthermore H. pylori was linked 
with both histological variants present in either the body or antrum of stomach. Such 
compelling evidence therefore persuaded the IARC (International Agency for Research 
on Cancer) in 1994 [Nyren et al, 1998] to classify this gram-negative bacterium as a 
group I carcinogen that presents a definitive contribution to the gastric cancer.
The direct link of gastric cancer and H. pylori has since been confirmed in further 
studies. Watanabe et al [1998] successfully demonstrated that long-term infection of H. 
pylori in Mongolian gerbils induced gastric adenocarcinoma. Tumours were present in 
37% of animals in this study and all consisted of well-differentiated intestinal type 
epithelium in the pyloric region. This corresponds to the intestinal type adenocarcinoma 
observed in humans, suggesting a direct involvement between H. pylori infection and 
gastric carcinogenesis.
However H. pylori infection cannot explain all epidemiological features. It has been 
observed in several developing countries that although the infection occurs at an early 
age, the frequency of gastric cancer is very low [Holcombe et al, 1992]. Additionally, 
although the male to female ratio of cancer is 2:1, infection is the same in both sexes. 
[Forman et al, 1998].
16
There is also increasing evidence that some gastric cancers are caused by an inherited 
predisposition. Familial factors account for ~8% of all stomach cancers and first-degree 
relatives of gastric cancer patients have an increased relative risk of ~3 fold [La 
Vecchia et al, 1992]. The down- regulation of the adhesion molecule E-cadherin 
resulting in loss of cell-cell adhesion and an increase in invasiveness is one such genetic 
abnormality that is especially common in poorly differentiated diffuse type gastric 
cancer [Guilford et al, 1998].
Prominent genetic alterations also play a role in tumourigenesis. Microsatellite 
instability (MI), which is involved in various cancers, is observed in 39% of all gastric 
cancers [Han, 1993]. Nakashima et al [1995] however noted the incidence increased to 
53.3% when including multiple gastric cancer cases and observed 78.5% of patients 
represented MI in at least one of their multiple cancers. This suggests that microsatellite 
instability has a more important role in the development of multiple cancers in the same 
host than in solitary gastric cancer. Microsatellite instability in hereditary nonpolyposis 
colon cancer (HNPCC) occurs due to germline mutations in the mismatch repair genes 
MSH2 and MLH1 and carriers of these mutations have a 4-fold risk of gastric cancer in 
addition to increased colorectal cancer [Lynch et al, 1996]. Yet these germline 
mutations are rarely observed in sporadic or familial non-HNPCC gastric cancer 
suggesting alternative genes to be involved in these cases.
Tumour progression of gastric cancer subtypes can also be related to genetic alterations. 
Overexpression of the p53 gene was shown to be related to tumour progression in 
diffuse type of gastric cancer as was the proto-oncogene c-met, which was also noted in 
advanced gastric cancer. Overexpression of the proto-oncogene c-erbB-2 however was 
significantly higher in the intestinal type and advanced stage. Loss of heterozygosity of 
APC (adenomatous polyposis coli) and DCC (deleted in colorectal cancer) was 
observed in 30% of intestinal type with the latter significantly detected in advanced 
stage [Wu et al, 1997]. Furthermore, the inactivation of APC gene is observed in -20% 
of sporadic gastric cancers suggesting a key role in initiation in sporadic gastric cancer 
[Hsieh, 1995].
Certain cytokines also have a role in this disease. Constitutive interleukin-8 (IL-8) 
expression was observed in both normal and inflamed gastric mucosa, with increased
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expression observed in the latter [Crabtree et al, 1994]. Similarly, interleukins l a  and 3 
(IL-la, IL-3), and granulocyte-macrophage colony stimulating factor (GMCF) were 
expressed in human gastric carcinoma cell lines [Ito et al, 1993, Dippold et al, 1991]. 
Furthermore, three polymorphisms in IL-1, which are believed to enhance production of 
IL-lp, have been associated with gastric cancer [El-Omar et al, 2000].
Other causative agents include smoking, which increases risk of disease to 1.8/2.2 
(intestinal and diffuse type respectively). Additionally diet has been implicated showing 
an inverse relationship between intake of fresh fruit and vegetables and the risk of 
gastric cancer [Ye et al, 1999].
2.2. IL-6 AND GASTRIC CANCER
There have been several recent studies carried out supporting a relationship between IL- 
6 and gastric cancer. IL-6 has been shown to act as an autocrine growth factor in some 
gastric carcinoma cell lines. In this study IL-6 mRNA was expressed and high IL-6 
levels secreted in 3 of 8 gastric carcinoma cell lines. This was further demonstrated by 
the addition of anti-IL-6 AB which suppressed cell growth [Ito et al, 1997].
Studies have also reported that serum IL-6 reflects disease status of gastric cancer and 
may be used as a serum marker to monitor disease progression [Wu et al, 1996]. Serum 
levels in patients with gastric cancer, benign gastric lesions, hepatitis-B patients and 
normal subjects were measured and the results showed that the mean serum levels in 
gastric cancer patients (mean ± Se 10.0 ± 9.5pg/ml) were significantly higher than in 
these control groups, (2.5 ± 0.3pg/ml, 2.6 ± 0.5pg/ml and 2.8 ± 0.9pg/ml respectively). 
Similar significantly higher results were also observed by comparing the median serum 
IL-6 levels. Further studies showed that of the six gastric cancer lines, five secreted IL- 
6 suggesting that gastric stromal cells secrete IL-6. In addition serum IL-6 levels 
correlated with disease progression and decreased after removal of tumour bearing 
tissues, thus resulting in a relationship between gastric cancer stages and IL-6. These 
results may thus indicate that the immune response directed against the tumour was 
inhibited by IL-6 [Wu et al, 1996].
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2.3. BARRETTS OESOPHAGUS
Barrett's Oesophagus is a pre-malignancy that has as yet eluded consensus upon 
definition, diagnosis and treatment. It is now generally accepted to be the replacement 
of squamous mucosa with metaplastic columnar epithelium and goblet cells in the distal 
oesophagus [Navaratnam and Winslet, 1998, Pereira et al, 1998]. The identification of 
columnar mucosa observed near the oesophageal junction however, causes uncertainty 
in ascertaining whether there is representation of Barrett's epithelium or gastric 
epithelium. This is due to difficulty in identifying the junction of oesophagus and 
stomach by the endoscopic techniques generally used to establish diagnosis. 
Furthermore the length of the segment has been in dispute as to its importance in the 
definition. In some cases BO is only represented if metaplasia is observed at a distance 
of at least 3cm. This therefore recognises the term 'short segment' Barrett's Oesophagus, 
indicated by columnar glandular mucosa within 2-3cm of the proximal edge of the 
gastric folds (Pereira et al, 1998). In contrast, by disregarding the length all metaplasia 
in this segment is regarded as Barrett's Oesophagus [Spechler et al, 1996, Spechler et al, 
1996b].
BO is observed predominantly in Caucasians, with a male to female ratio of 2:1 
[Navaratnam and Winslet, 1998]. This pre-malignant condition can develop into 
invasive cancer through a series of steps. These are characterised by low-grade 
dysplasia and high-grade dysplasia, which eventually develops to adenocarinoma 
[Hammeteman et al, 1989]. Patients with BO are at 3-5- fold more at risk in developing 
oesophageal adenocarcinoma [Hameeteman, 1989] and an estimated 75% of all 
adenocarcinomas of the oesophagus originate from BO.
Barrett's Oesophagus was first reported in 1906 by Tileston who observed a peptic ulcer 
in the oesophagus that showed close resemblance to ulcers detected in the stomach. 
However in 1950 Norman Barrett published a report that supporting the view of other 
investigators since and suggested that the organ was actually a tubular segment of 
stomach in patients with a congenitally short squamous lined oesophagus [Spechler et 
al, 1996].
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The true prevalence of BO is difficult to determine although it is estimated that 1% of 
the population are affected. This is due to many patients being asymptomatic. For those 
patients that do experience symptoms such as heartburn, a significant proportion self- 
medicate with antacids when affected with mild disease severity [Cameron et al, 1990]. 
However, once cancer develops, the prognosis is poor unless there is early diagnosis. 
Survival rates after surgical resection are placed at <20% in the next 5 years unless 
treated early, when 5 year survival is >90%. Although all ages can be affected, the 
median age for development of BO is approximately 40 years, whilst mean age for 
cancer diagnosis is approximately 60 years [Cameron et al, 1992]. The increasing 
prevalence observed with increasing age suggests that Barrett’s Oesophagus is an 
acquired abnormality.
Gastro-oesophageal reflux (GORD) has been recognised as the main aetiological factor 
and -12% of patients experiencing GORD symptoms were diagnosed as having BO 
[Winters et al, 1987]. Acid and bile reflux occurs characteristically when there is failure 
of the lower oesophageal sphincter secondary to inappropriate transient relaxation of 
LOS, leading to retrograde oesophageal flow. [Navarantnam and Winslet, 1998]. It has 
been shown that acid reflux is directly related to development of BO, whilst bile reflux 
may have a synergistic role [Champion et al, 1994].
There is increasing evidence that molecular abnormalities are involved in BO and its 
progression to BO associated adenocarcinoma. The development of adenocarcinoma 
includes mobilisation of cells from G0 to G, [Reid et al, 1993]. Loss of heterozygosity 
studies, detected in premalignant epithelium and oesophageal adenocarinoma have 
indicated allelic imbalance of 4q, 5q, 9p, 12q, 17p and 18q [Gleeson et al, 1998], 
suggesting involvement in BO progression. The observations of p53 gene mutations, 
which are located on chromosome 17p, in Barrett's adenocarcinomas further confirm 
association with malignant transformation [Neshat et al, 1994, Hamelin et al, 1994]. 
Genetic instability has also been related to BO. Microsatellite instability initially 
observed in diploid cells and secondary alterations in aneuploid cells of BO 
oesophageal adenocarcinomas suggests that MI may continue through the multiple 
stages of neoplastic progression as well as at onset. [Meltzer et al, 1994]. To date, there 
have been no studies in the relationship of IL-6 to Barrett's Oesophagus.
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2.4. RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a common chronic inflammatory disorder involving the 
synovial membranes of multiple joints, which result in cartilage and bone invasion. 
Unsuccessful treatment eventually leads to joint destruction resulting in loss of 
function, disability and increased mortality [Pope, 1996]. RA is a relatively recent 
condition and first described in 1800 by Austin-Jacob and Landre-Beauvais, who 
considered it to be a form of gout. It was not until 1858 however that Garrod first 
termed this condition as 'Rheumatoid arthritis' [Landre-Beauvais, 2001].
RA affects about 1% of the population and about 5% of women over 65 years of age 
[Deighton, 1994]. The disease is more common in women at a rate of 3:1 over men and 
although it generally occurs later in life at approximately 40-50 years, all ages can be 
affected. This disease can eventually restrict the patients' ability to work thus having an 
important impact in economy.
Mortality in patients with RA often occurs at an earlier age than the general population. 
Evidence reports a decrease in survivorship of approximately 50% [Mitchell et al,
1986]. The two major causes of death however (i.e. cardiovascular disease and 
malignancy) remain the same in both rheumatic patients and the general population. Yet 
in RA patients, there is an increased mortality risk from infection or sepsis and from 
gastrointestinal causes. Additionally, increased mortality has been directly linked to 
complications of RA such as vasculitis, cervical subluxation, amyloidosis and 
rheumatoid lung (Mitchell et al, 1986).
The pathogenesis of RA has been described in five overlapping stages by Harris [1990]. 
The causes of RA are presently unknown although it is increasingly clear that both 
environmental and inherited factors have a role. Environmental triggers suggested 
include infectious agents such as viruses and bacteria. The genetic factors shown to be 
consistently involved in a predisposition to RA are in the HLA-DR locus on the MHC 
situated on the short arm of chromosome 6. Studies have shown that 93% of patients 
carry HLA-DR4, HLA-DR1 or both [Stastny, 1978].
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HLA-DR4 can be further divided into 5 subtypes: Dw4, DwlO, Dwl3, Dwl4, and 
Dwl5 [Gregersen et al, 1987]. It has been determined that only the subtypes Dw4, 
Dwl4, and Dwl5 were associated with RA whilst DwlO and Dwl3 were not [Stastny et 
al, 1978, Nepom et al, 1986]. The subtypes associated with RA shared a common 
sequence of 5 amino acids in the 3rd hypervariable region suggesting a critical area 
relating to RA susceptibility. A similar sequence at the 5aa stretch was also observed in 
HLA-DR1, which further supports this hypothesis.
Studies have also suggested that HLA-DR4 may also be related to disease severity. On 
the basis of radiological findings in the hand, RA patients with HLA-DR4 had a more 
destructive disease [Calin et al, 1989] than those who did not. Supporting evidence was 
observed when RA patients carrying the disease-associated alleles on both 
chromosomes were more likely to develop severe destructive disease.
Disease severity has also been observed with HLA-DRB1. Most severe rheumatoid 
arthritis was identified with patients homozygous to HLA-DRB 1*0401 or 0404, and 
combinations of 0401 with 0404 or 0408. This suggests that genotyping may provide 
useful predictive biomarkers [Weyand et al, 1992].
Non-inherited factors relating to HLA antigens also influence susceptibility to RA. DR4 
non-inherited maternal antigens (NIMA) were increased in DR4 negative patients 
compared to DR4 non-inherited paternal antigens (NIPA). This therefore suggests that 
patients who were in contact to DRB 1*0401 and or *0404 positive HLA antigens 
during the foetal period have an increased risk of RA. It is suggested this may be due to 
positive mother's T cells, molecules or peptides influencing the T cell of the foetus [Van 
der Horst-Bruinsma et al, 1998].
Interleukin-1 (IL-1) is another factor that is associated with RA. Its biological activity 
was first observed in exudate synovial fluids [Wood et al, 1983]. Elevated IL-1 has 
since been observed in plasma of RA patients [Eastgate et al, 1988] with IL-1 p showing 
correlation with disease activity. Joint damage has also been reported to correlate with 
IL-1 production, suggesting a pivotal role in this process and a possible target for 
therapy [Miyasaka et al, 1988]. A single nucleotide polymorphism at -889 in IL-1 a  has 
been shown to be genetically associated with juvenile rheumatoid arthritic patients
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[McDowell et al, 1995] and chronic polyarthritis [Jouvenne et al, 1999], suggesting a 
contribution to the pathogenesis of these diseases and a possible prognostic marker.
High concentrations of TNF-a have also been reported in synovial fluids from RA 
patients [Saxne et al, 1988]. Additionally transgenic mice for a human 3' modified TNF- 
a  developed inflammatory synovitis in the joints, suggesting deregulated production of 
TNF aids in the pathogenesis [Keffer et al, 1991].
In vitro studies have shown that IL-8 is released from rheumatoid mononuclear cells 
isolated from bone marrow, peripheral blood, and synovial fluid, with highest 
production observed from the last source [Seitz et al, 1991].
Specific polymorphisms and associated haplotypes in Interleukin-10 (IL-10) have also 
been directly associated with RA. A significant over-representation of the IL10.R2 
allele, located upstream of the coding region, was detected in RA patients, suggesting 
that IL-10 may have an active role in the pathogenesis of this disease [Eskdale et al, 
1998]. Further association was observed with the low IL-10 producing haplotype ATA 
and severity of juvenile rheumatoid arthritis [Crawley et al, 1999].
The other inherited factor that is associated with RA is the female gender. A possible 
role for exogenous female sex hormones was suggested in a study by the Royal College 
of General practitioners in 1978, showing that oral contraceptives protected against 
development of RA. Since then however, there have been extensive studies with various 
findings thus providing inconclusive results. Endogenous sex hormones have also been 
implicated in the aetiology of RA. Studies have observed consistently lower levels of 
the immunosuppressive hormone testosterone in men with RA [Spector et al, 1988]. 
Furthermore, an association was observed between the diurnal rhythm of prolactin 
levels and disease activity [Chikanza et al, 1990]. This study combined with the 
presence of prolactin receptors on T and B lymphocytes [Gagnerault et al, 1993] may 
suggest there is an interaction between increased prolactin levels and the immune 
system. These findings compliment the recent study on the effects of breast-feeding. 
Women who developed RA within 12 months after their first pregnancy were more 
likely to have breast-fed [Brennan and Silman, 1994]. The risk of RA development was 
observed highest for first-born (5.4) and greatest amongst women who delayed 
motherhood till after their 29th year (13.8). In breast-feeding mothers, there are low
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levels of anti-inflammatory steroids and high prolactin levels. This therefore suggests 
that the prolactin may therefore act as a stimulus for the development of RA.
2.5. IL-6 AND RHEUMATOID ARTHRITIS
In RA, some of the abnormalities seem to be related to IL-6. Studies have shown that 
cells isolated from the synovial fluid of patients with RA constitutively expressed IL-6 
mRNA [Hirano et al, 1988]. Additionally, significantly elevated levels of IL-6 were 
observed in the synovial fluid of RA patients in comparison to osteoarthritic patients 
[Housiau et al, 1988]. When IL-6 from serum and synovial fluid was detected from RA 
individuals, the latter source produced levels ~1000 fold higher than the former. This 
suggests that the source of IL-6 is from the rheumatic joint [Brozik 1992]. Similarly, 
significantly elevated serum IL-6 levels were also detected in patients with active 
systemic -onset juvenile rheumatoid arthritis. However these remained similar to 
controls during remission, suggesting that the high IL-6 levels relate to joint 
inflammation [De Benedetti et al, 1991] and contribute to local and systemic arthritic 
manifestations [Gueme et al, 1989].
Polymorphisms detected in IL-6 gene and identified with restriction enzymes MspI and 
Bglll have been studied in relation to Rheumatoid arthritis, but have shown no 
association [Fugger et al, 1990, Blankenstein et al, 1989]. However, the polymorphism 
at -172 has shown significant association to this disease, as mentioned earlier. Studies 
in JRA patients have shown that the increased serum levels result from a difference in 
the control of IL-6 expression by the polymorphism at -172. When the constructs (- 
172G and -172C) were stimulated by LPS or IL-1 in a luciferase reporter system 
transiently transfected into HeLa cells, the transcriptional activity for -172G construct 
increased significantly in relation to the unstimulated level. In contrast, the -172C 
construct showed lower expression than the -172G construct when unstimulated and its 
activity did not increase after stimulation. Furthermore, plasma levels of IL-6 in healthy 
subjects were significantly lower when associated with the -172C allele than when the - 
172G allele was present. These results combined with the significantly less common CC 
genotype in S-JCA may indicate the reason for increased IL-6 levels in comparison to 
the control population [Fishman et al, 1998]. Similarly, elevated interleukin-6 plasma 
levels were regulated by -172 polymorphism of the IL6 gene in primary Sjogren's 
syndrome (pSS) and this correlated with the clinical manifestations of the disease
24
[Hulkkone et al, 2001]. However, they noted that the -172 allele frequencies were 
similar in patients and normal subjects and hence the G/C polymorphism does not 
predispose patients to pSS. In contrast, Collado-Escobar et al [2000] determined that the 
polymorphism at -172 played no role in susceptibility to Ankylosing Spondylitis. These 
studies therefore suggest that there are additional variations in close proximity, which 
are contributing to the overall effect.
Previous studies in cytokines such as TNF and IL-10 [Gallagher et al, 1997, Eskdale et 
al, 1999] have shown polymorphisms to associate to one another as haplotypes across 
the locus. The aim of this project was therefore to examine four polymorphic elements 
in the human IL-6 gene, three point mutations in the 5' promoter and one VNTR in the 
3' region, and determine their relationship to one another. Furthermore, these 
polymorphic elements were then to be observed in malignant and autoimmune cohorts 
and determine the possibility of disease related associations.
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MATERIALS AND METHODS
3.1. PATIENTS
Patient and control samples were obtained from a number of sources. DNA from 115 
healthy unrelated individuals from the West of Scotland were obtained and provided by 
the tissue typing unit of Glasgow Royal Infirmary as the control group. At the time of 
sampling no individuals were known to be suffering from either a malignant or 
autoimmune disease. DNA from 69 patients classed with Gastric cancer and 98 patients 
with Barrett's Oesophagus were available in the laboratory, having been obtained from a 
previous project. However additional DNA was extracted to replenish stocks. The 
Barrett's Oesophagus patients were diagnosed with benign and malignant forms and 
separated accordingly to provide 51 samples of benign Oesophagus and 47 of malignant 
oesophagus.
In order to compare the distribution of IL-6 alleles in an ethnically distinct control 
population, 53 control African American DNA samples were obtained from Dr Janet 
McNicholl, Centres for Disease Control, Atlanta. A group of 109 rheumatoid arthritic 
patients from this source were also examined.
3.2. ISOLATION AND STANDARDISATION OF GENOMIC DNA
DNA was extracted from both frozen blood and tissue sections embedded in paraffin. 
Extraction from frozen blood was achieved by following the 'Genomix kit' protocol for 
'Old Blood' exactly. DNA from tissue sections was achieved by first soaking the slides 
in xylene for 10 minutes to remove the paraffin, followed by 30 seconds in two more 
xylene baths, in order to remove remaining traces. The tissue sections were then 
rehydrated. This was achieved by dipping the slides for 30 seconds in a series of 
decreasing alcohol concentrations. The baths were at concentrations of 100%, another 
100%, 90% and 70%, before soaking in tap water and distilled water. The tissue 
sections were then scraped off the slide and suspended in PCR buffer. Equal volumes of 
PCR buffer and Tween containing lpg/pl proteinase K was added before incubating at 
37°C for three days. This allowed digestion of the cells. After spinning down, the pellet 
was removed, leaving genomic DNA in solution.
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The amount of DNA obtained was determined by spectrophotometric analysis. A 1:100 
dilution of the DNA was placed in a cuvette and absorbencies at 260nm and 280nm 
obtained. The absorbance at 260nm provided the concentration of nucleic acid in the 
sample and the absorbance at 280nm provided the RNA concentration. The ratio 
between 260/280 allowed estimation of the purity of the nucleic acid. An O.D ratio 
value of 1.8 and above was taken to show that a pure DNA preparation had been 
obtained. Calculation of the 260nm reading multiplied by 50 (1 O.D = 50ng), multiplied 
by 100 (dilution factor), provided the amount of DNA in lpl.
3.3. GENOTYPE DETERMINATION OF 5T SNP
The 3 point mutations studied in this thesis were at positions -594, -570, and -172. The 
position numbers correspond to the nucleotide number of the sequence in Accession 
number AF048962 [Faulds et al]. Genotyping at the three point mutations studied in 
this thesis was achieved by amplification of the region encompassing the three sites by 
PCR, followed by restriction enzyme digestion.
Amplification was carried out in two stages. Firstly an 861bp segment (primers 6PR-1 
and 6PR-2) of the IL-6 promoter sequence (shown in the above accession number) was 
amplified. This product then became the template DNA for nested (primers Nla-F and 
Nla-R) and semi-nested PCR experiments (primers 6PR-1 and Fok/Fnu-R). This 
allowed further amplification thus increasing product concentration hence allowing 
clearer digestion detection to be obtained. Fig.2 contains the position and direction of 
the primers used for these analyses. Additionally, the three SNPs are indicated in 
capitals, with the alternative bases shown under the main sequence, the codon for the 
initiating methionine (ATG) and the transcription site (T).
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FIGURE 2. Polymorphic elements in the human IL-6
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Optimised amplification of 861bp region
In a 50pl final reaction volume 50-150ng DNA was amplified with 0.15pM each 
primer, 5pi of lOx Buffer IV (Advanced Biotechnologies), 200pM of each 
deoxyribonucleotide triphosphates (dATP, dTTP, dCTP, dGTP), 1.5mM MgCl 2 (AB) 
and 2U Taq DNA polymerase (AB). The primers were designed with consideration to 
maintaining a comparable length and similar Tm values. The primers deemed suitable 
were as follows:
5’ GGA.GTC.ACA.CAC.TCC.ACC.TGG 3’ 6PR-1
5’ GTG.ACT.GAC.AGC.AGA.GCT.GG 3’ 6PR-2
Replacing the template DNA with sterile water in order to confirm positive results was 
also set up as a mandatory negative control for every experiment.
The PCR conditions were carried out in a 40-well Biometra thermocycler and 
comprised an initial denaturation step at 94°C for 5 minutes, followed by 35 cycles of 
94°C, 56°C and 72°C each for 1 minute. A final extension step at 72°C for 1 minute 
completed the reaction. 5pi of PCR product was mixed with 5pi orange dye. A (|)X174 
RF DNA/Hae III fragment ladder (Gibco) to confirm a correct size band and the 
negative control were added adjacent to the PCR product. These were loaded on a 2% 
lx TAE agarose gel (Nusieve 3:1) stained with ethidium bromide at a concentration of 
0.08% immersed in lx TAE buffer and run at 50mA.
Optimised amplification of -594 and -570 SNP by semi-nested PCR
The 861 bp product obtained from the original amplification was used as the template 
DNA. The reagents remained exactly the same as above except the reverse primer was 
replaced with the following:
5’ GGA.GTC.ACA.CAC.TCC.ACC.TGG 3’ 6PR-1
5’ CCA.AGC.CTG.GAT.TAT.GA 3’ Fok/Fnu-R
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The reaction conditions remained the same except that an annealing temperature of 
49°C replaced the previous 56°C. The resulting 152bp product produced was checked as 
above for contamination.
Endonuclease digestion of Fok-I allele
The -594 AJG SNP first observed by Faulds et al [Accession number AF048962] was 
detected by the restriction enzyme Fok-I. A sequence C[A]TCC provides a cleavage site 
for this enzyme at the 5* end of the first C. The presence of G in the brackets prevents 
cleaving.
In a total volume of 25pl, lOpl of amplified DNA was digested by adding 2.5pl of lOx 
Buffer (New England Biolabs) and 2U Fok-I enzyme (New England Biolabs). After 
incubation at 37°C for 3 hours, 5 pi orange dye was added to the digested product. This 
was run against a <|)X174 RF DNA/Hae III (Gibco) fragment ladder on an ethidium 
bromide stained 3% agarose gel in lx TAE buffer at 50mA until clear separation was 
observed under the UV illuminator.
An adenine nucleotide provides a cleavage site in the 152bp band producing two bands 
of 66bp and 86bp where as a guanine nucleotide annuls the site and the thus band 
remains 152bp. A 1*1 homozygote (AA) was detected by the two bands of 66bp and 
86bp while a 2*2 homozygote (GG) was detected by the single 152bp band. A 1*2 
heterozygote (AG) was observed by the detection of bands 66bp, 86bp and 152bp. A 
representative gel picture is illustrated in fig. 3.
Endonuclease digestion of Fnu4H-I allele
The restriction endouclease Fnu4-HI was used to detect the -570 G/C SNP. A sequence 
of GCN[G]C where N represents any nucleotide provides a cleavage site at SNP site. 
Similar conditions were used to digest the amplified product as for Fok-I allele except 
2.5U Fnu4HI enzyme was added.
A guanine nucleotide creates a cleavage site for this enzyme producing bands of sizes 
80bp and 72bp. A cytosine nucleotide abolishes the site and the band remains at 152bp.
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Lane 1: X174RF DNA/ HAE III ladder 
Lane 2: Undigested 152bp fragment
Lane 3: Homozygote -594.A by Fok-I endonuclease digestion 
Lane 4: Heterozygote -594.G/A by Fok-I endonuclease digestion 
Lane 5: Homozygote -594.G by Fok-I endonuclease digestion 
Lane 6: Homozygote -570.G by Fnu4H-I endonuclease digestion 
Lane 7: Heterozygote -570.C/G by Fnu4H-I endonuclease digestion 
Lane 8: Undigested 295bp fragment
Lane 9: Homozygote -172.G by Nla-III endonuclease digestion 
Lane 10: Hom ozygote-172.C by Nla-III endonuclease digestion 
Lane 11: Heterozygote-172.G/C by Nla-III endonuclease digestion
FIGURE 3 Agarose gel displaying endonuclease digestion of polymorphisms at 
positions -594, -570 and -172 within the IL-6 locus.
Again a 1*1 homozygote for C alleles was detected by the two small bands and a 
homozygote 2*2 GG by the larger single band. A heterozygote 1 *2 CG was detected by 
all three bands. This can be observed in fig.3.
Optimised amplification of -172bp SNP bv nested PCR
The original 861bp product was again used as the template DNA for this reaction. The 
reagents remained exactly the same except the primers were substituted with the 
following internal primers:
5’ TTG.TCA.AGA.CAT.GCC.AAA.GTG.CT 3’ Nla-F 
5’ CAT.CTC.CAG.TCC.TAT.ATT.TAT.TG 3’ Nla-R
These primers were designed by O.O. Olomolaiye et al (1998). The PCR conditions 
remained the same except an annealing temperature of 52°C for 1 minute was used. This 
amplification protocol produced a 295bp product encompassing the -172 SNP.
Endonuclease digestion of Nla-III allele
The -172G/C SNP was first observed by 0 .0  Olomolaiye et al [1998] and detected with 
the restriction endonuclease Nla-III. This enzyme recognises a [C]ATG sequence and 
cleaves at the 5' end of the C base.
lOpl of amplified DNA was digested with 2.5pl of lOx Buffer, 5U Nla-III enzyme and 
0.25pi of lOOx BSA (all NEB) in a 25pi reaction volume. After 3 hours of incubation at 
37°C the digested products were observed on an agarose gel as above.
In the 295bp band there are already two cleavage sites present producing digested 
products of 233bp, 53bp and 9bp. A cytosine at -172 produces an additional restriction 
site cleaving the 233bp into 122bp and 11 lbp. A guanine nucleotide does not allow this 
cleaving. Therefore a 1*1 homozygote for allele C was detected by bands at 122bp,
11 lbp and 53bp. The additional 9bp was too small to be observed on the 3% agarose 
gel. A 2*2 homozygote for G was detected by the presence of 233bp and 53bp (9bp too 
small to be observed). The heterozygote CG genotype was observed by bands of 233bp, 
122bp, 11 lbp and 53bp (9bp too small to be detected), as shown in fig. 3.
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3.4 GENOTYPE DETERMINATION OF 3' VNTR
The 3' variable number tandem repeat (VNTR) first observed by Bowcock et al [1989] 
are a group of repetitive non-coding DNA sequences. These examples of sequences are 
becoming increasingly important as markers in the genome.
Optimised amplification of 3* VNTR
In a 25 pi reaction volume lOOng of DNA was added to 200pM of dTTP, 200pM of 
dCTP, 200pM of dATP, 20pM dCTP, 3mM MgCl2, 2.5pl of lOx Buffer (Bioline), 0.5U 
Bioline Taq, lpM  of each primer and 0.03pl a 32 P. The primers used were designed by 
Bowcock et al [1989] and were of the following sequence:
5’ GCA.ACT.TTG.AGT.GTG.TCA.CG 3’
5’ GAC.GTG.ATG.GAT.GCA.ACA.C 3’
The amplification conditions were in accordance to those described by Bowcock et al 
and comprised of an initial denaturation step at 94°C for 5 minutes, followed by 28 
cycles of 94°C for 15 seconds, 55°C for 30 seconds and 72°C for 1 minute. Each PCR 
had both negative and positive controls to detect contamination and confirm consistency 
across all the PCR experiments.
Denaturing PAGE
The products were separated on a 3.5% denaturing polyacrylamide gel produced by 
8.75ml of 19:1 acrylamide (DNA sequencing grade): N,N-methylenebisacrylamide gel 
mix, lx TBE, 7M urea, 50pl TEMED and 750pl 10% w/v ammonium persulphate. Prior 
to loading on a preheated gel, 4pl formamide loading buffer (including lOmM EDTA) 
was added to the products, which were then denatured at 80°C for 10 minutes. These 
were then immediately placed on ice to prevent renaturation. 4pl of each sample was 
loaded on the gel and run on a Stratagene gel rig at 75W for 5 hours. The gel was then 
dried for 1 hour and autoradiographed with Kodak film.
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The 3' VNTR alleles were compared and determined individually by two independent 
people. Control DNA's with a range of genotypes were run on every gel in order to 
assume consistency of allele calling.
3.5 STATISTICAL ANALYSIS
After obtaining individual allele and genotype frequencies at the 5'SNP's and 3'VNTR, 
the polymorphisms were compared with each other. This allowed detection of possible 
relationships amongst the polymorphisms across the promoter and gene. These 
comparisons were achieved by constructing 2x2 contingency tables and using %2 
analysis on Minitab for Windows software. A probability of less than 0.05 was deemed 
significant. Due to the number of allelic combinations possible with 3'VNTR and a 
5'SNP, these multiple comparisons were Bonferroni corrected (pc). A probability of less 
than 0.05 after Bonferroni correction was deemed to be very significant. Power analysis 
was also carried out to determine the power of detecting a significant difference with 
the cohort size by calculating against an odds ratio (OR) of 2. This test was carried out 
using the ‘PS Power and Sample Size Calculations’ program.
These analyses were tested in all the populations. Furthermore comparisons between the 
patient groups and the controls were carried out in order to show possible significant 
variations in diseases. In addition comparisons between the different disease groups of 
the same ethnicity were analysed. Finally, a comparison with the two ethnic control 
groups was also tested in order to highlight any conceivable inconsistencies. The 
comparisons at each stage examined possible differences in allele and genotype 
numbers, allele and genotype associations, and haplotype observations.
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RESULTS
4.1. Allelotvpe and genotype data of West of Scotland control 
population
The genotypes of the West of Scotland normal control population are shown in Table 2. 
The allele frequencies and their genotype counterparts for the three single nucleotide 
polymorphism (SNP) sites and 3' variable number tandem repeats (VNTR) are shown in 
Table 3. The results show that at the -594 polymorphic site, allele A was present at 
41.7% and allele G at 58.3%. Similarly, at the -172, alleles C and G were present 44.2% 
and 55.8% respectively. At -570, allele C was rarely observed (4.5%) whilst allele G 
was common at 95.5%.
Chi-square analysis showed strong significant associations between the point mutations
in the 5' promoter region. Alleles A and C at positions -594 and -172 respectively were
2
seen in strong linkage disequilibrium (x =88.268, p<0.00001), as were the two G
alleles at these sites (i.e. p<0.00001). Additionally, -594.A and -570.G were
2
significantly associated as were -594.G and -570.C (x =5.0960, p=0.024). No 
significant association was observed between either alleles at -172 and -570.
Based upon the observed associations and the allele distribution in the 5' promoter 
region, the following 3 haplotype families were considered to be prominent:
-594.A -570.G -172.C
-594.G -570.G -172.G
-594.G -570.C -172.G
accounting for 98.9% of the total possible haplotypes. These groups can subsequently 
be proposed terms that both differentiate the different allele combinations and 
determine their respective frequencies. It is suggested they be termed IL6.01, IL6.02, 
and IL6.03 respectively. The two additional haplotype families detected were too 
infrequent to be suggested as prominent haplotype families in this population.
35
TABLE 2
The results of the normal control West of Scotland population
SAMPLE 5’
NO.
FOK-1
REGION
FNU4H-I NLA-III
-594 -570 -172
30001 AG nd CG
30002 AG nd CG
30003 AA GG CC
30006 GG GG GG
30007 AG GG CG
30008 AG GG CG
30009 GG GC GG
30010 AG GG GG
30011 AG GC CG
30012 AG GG CG
30013 AA GG CC
30014 AG GG CG
30015 AG GG CG
30016 GG GG GG
30017 AG GG CC
30018 AG GG CG
30019 GG GG GG
30020 GG GG GG
30021 AA GG CC
30022 AG GG CG
30023 GG GG nd
30024 GG nd GG
30025 GG GC GG
30027 AG GG CG
30028 AG GG CG
30029 nd nd nd
3’
VNTR
4*4
3*7
nd
4*4
3*7
nd
nd
nd
3*4
3*6
3*3
nd
nd
nd
nd
3*4
4*6
4*7
nd
3*4
3*13
nd
nd
3*7
3*9
3*7
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NO.
30030
30031
30032
30033
30034
30036
30037
30038
30039
30040
30041
30042
30043
30044
30045
30046
30047
30049
30050
30051
30052
30053
30054
30056
30057
30058
30059
30060
30061
FOK-1
REGION
FNU4H-I
-594 -570
AG GG
GG GC
AG GG
GG GC
AG GG
AG GG
AG GG
AG GG
GG GG
GG GG
AA GG
AG GG
GG GG
nd nd
GG GG
GG nd
AG GG
AG GG
AG GG
AG GG
AG GC
AG GG
AG GG
AA GG
AG GG
nd nd
AA GG
GG GC
GG GG
3’
VNTR
NLA-III
-172
nd 3*7
CG 7*7
CG 3*4
nd 7*7
CG 3*4
CG 3*7
CG 3*7
CG 3*4
GG 6*7
GG 7*7
CC 3*3
CC 3*3
GG 4*4
nd 3*4
GG 4*4
GG 4*4
CG nd
CG 3*4
CG 3*7
CG 3*4
CG 3*7
CG 3*4
CG 3*7
CC 3*3
CG 3*4
CG 3*4
CC 3*3
GG 4*7
GG 4*7
NO.
30062
30063
30064
30065
30066
30067
30068
30069
30070
30072
30073
30074
30075
30076
30077
30078
30079
30080
30081
30082
30083
30084
30085
30086
30087
30088
30089
30090
30091
FOK-1
REGION
FNU4H-I
-594 -570
GG GG
AG GG
AA GG
GG GG
AG GG
AG GC
AG GG
AG GG
AA GG
AG GG
GG GG
GG GG
GG GG
AG GG
AG GG
AG GG
AG GG
AA GG
AG GG
GG GG
AA GG
AA GG
AA GG
AA GG
AA GG
AG GG
GG GG
GG GG
nd nd
3’
VNTR
NLA-III
-172
GG 4*4
CG 3*4
CC 4*4
GG 7*8
CG 3*4
CG 4*7
CG 3*4
CG 3*4
CC 3*3
CG nd
GG nd
GG nd
GG nd
CG nd
CG nd
CG nd
CG 3*7
CC 3*3
CG 3*8
GG 4*8
CC 3*3
CC 3*3
CC 3*3
CC 3*3
CC 3*3
CG nd
GG 4*7
GG 4*4
CC 3*3
SAMPLE 5’ 3’
NO. REGION VNTR
FOK-1 FNU4H-I NLA-III
-594 -570 -172
30092 AG GG CG nd
30093 AG GG CG 3*4
30094 nd nd nd 4*7
30095 nd GG CG 3*4
30096 GG GC GG 6*7
30097 AG GG CG 3*7
30098 nd nd nd 4*7
30099 AG GG CG 3*4
30100 GG GG GG 4*4
30101 AG GG CG nd
30102 AG GG CG 3*7
30103 GG GG GG 6*7
30104 nd nd nd 3*7
30105 AG GG CG 3*4
30106 GG GG GG 7*8
30107 AA GG CC 3*3
30108 AG GG CG 3*4
30109 AG nd CG 3*7
30110 GG GG GG 4*4
30112 AA GG CC nd
30113 AA GG CC 3*3
30114 GG GG GG 4*4
30115 AG GG CG 3*4
30136 GG GG GG 3*7
30137 GG GG GG 3*7
30138 GG GG GG 3*7
30158 nd nd CG 4*4
30172 AG GG CG 3*4
nd = not defined
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TABLE 3
Allele distribution at four polymorphic loci in the normal control West
of Scotland population
^OCUS Allele Number Genotype Number
Observed (%) Observed
■594 A 86 (41.7) A*A 17(16.5)
G 120 (58.3) A*G 52 (50.5)
G*G 34 (33)
•570 C 9 (4.5) G*G 90 (91.8)
G 189 (95.5) G*C 9 (8.2)
C*C 0 (0)
172 C 92 (44.2) C*C 20(19.2)
G 116(55.8) C*G 52 (50)
G*G 32 (30.8)
S'VNTR 3(61Obp) 75 (42.1) 3*3 15 (16.9)
4 (616bp) 56 (31.5) 3*4 23 (25.8)
6 (639bp) 5 (2.8) 3*6 1 (1.1)
7 (648bp) 36 (20.2) 3*7 18(20.2)
8 (658bp) 4 (2.2) 3*8 1 (1.1)
9 (672bp) 1 (0.6) 3*9 1 (1.1)
13 (773bp) 1 (0.6) 3*13 1 (1.1)
4*4 12(13.5)
4*6 1 (1.1)
4*7 7 (7.9)
4*8 1 (1.1)
6*7 3 (3.4)
7*7 3 (3.4)
7*8 2 (2.2)
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These were:
-594.G -570.G -172.C
-594.A -570.G -172.G
Analysis of the 3’ VNTR displayed 7 irregularly sized alleles in the West of Scotland 
control population, although an additional 6 alleles were observed in the various disease 
groups studied from the West of Scotland area. The individual genotypes can be 
observed in Table 2. The allele sizes in the West of Scotland control population ranged 
from 610bp to 773bp and the proportions of the respective alleles for the control 
population are shown in Table 2 and illustrated in fig.4. The data show that allele 3 is 
most frequent followed by alleles 4 and 7 (42.1%, 31.5%, and 20.2% respectively). The 
four prominent genotypes, 3*4 (25.8%), 3*7 (20.2%), 3*3 (16.9%) and 4*4 (13.5%) 
accounted for 76.2% of the total.
Associations between the multi-allelic 3' VNTR and point mutations in the 5' region 
were seen with alleles 3, 4, 6, and 7. Allele 3 was strongly associated with both -594.A 
and
-172.C (x 2=57.388, pc<0.00013, x2=58.434, pc<0.00013). A weak association between 
-570.G and 3' VNTR allele 3 was also observed but which diminished when corrected 
for multiple comparisons (x2 =5.095, p=0.024, pc=0.312). 3' VNTR allele 4 was 
associated with -594.G and -172.G (x2 =11.908, pc=0.0078, x2=15.919, pc=0.00013 
respectively), but not with either of the -570 alleles. Again this was seen with allele 6, 
where weak associations with -594.G and -172.G were observed which became 
insignificant when Bonferroni corrected (x2 =4.3090, p=0.0379, pc=0.4927, % =5.1240, 
p=0.0236, pc=0.3068). Finally there was a strong association between IL-6 3' VNTR 
allele 7 and -594.G, -172.G and -570.G =13.147, pc=0.0039, % =10.52, pc=0.0156,
% =13.263, pc=0.0039 respectively).
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Lane 6: 4/6 
Lane 7: 3/6 
Lane 8: 3/7 
Lane 9: 3/8 
LanelO: 3/9
Gel by Mrs. J. Eskdale
Lane 1: 123bp ladder 
Lane 2: lOObp ladder 
Lane 3: water blank 
Lane 4: 3/4 
Lane 5: 4/13
Lane 11:3/8 
Lane 12: blank 
Lane 13: 8/8 
Lane 14: blank 
Lane 15: lOObp ladder 
Lane 16: 123bp ladder
FIGURE4. Demonstration of allel es sizes at the IL-6 3’VNTR locus
Based upon the associations observed and the allele distribution it is postulated that 
there are four potential extended relationships between 5' SNP and 3' VNTR. 
Furthermore it is proposed that these associations spanning the IL-6 gene functioned as 
haplotypes:
i. -594.A -570.G -172.C 3' VNTR.3
ii. -594.G -570.G -172.G 3' VNTR.4
iii. -594.G -570.G -172.G 3’ VNTR.7
iv. -594.G -570.C -172.G 3' VNTR.7
The 2nd and 3rd extended associations contain the -570.G allele by default. It is 
suggested that the haplotypes be termed IL6.0103, IL6.0204, IL6.0207 and IL6.0307 
respectively. The former part of the terminology relates to the 5' promoter haplotype 
families as shown earlier, and the latter part of the terminology further differentiates 
one haplotype from another by making use of the 3' allele.
In support of these proposed haplotypes, 13 individuals were homozygous for IL6.0103, 
8 were homozygous for IL6.0204 and one for IL6.0207. Furthermore, genotyping data 
were consistent with a further 18 being heterozygous for IL6.0103/ IL6.0204 and 9 
more for IL6.0103/ IL6.0207. Subtraction of these haplotypes from the population 
revealed a number of supposed haplotypes and their distribution can be observed in 
Table 4. It can be seen that these four haplotypes mentioned potentially account for 
87% of the total genotypes observed. The remaining were seen too infrequently to be 
suggested as prominent haplotypes in this population.
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TABLE 4
Putative haplotypes observed in the West
of Scotland Control population
5' 3f Number
-594 -570 -172 VNTR observed
A G C 3 60 (41.1)
A G c 4 3 (2.1)
G G G 3 3 (2.1)
G G G 4 41 (28.1)
G G G 6 5 (3.4)
G G G 7 21 (14.4)
G G G 8 4 (2.7)
G G G 9 1 (0.7)
G C G 4 1 (0.7)
G C G 7 5 (3.4)
G G C 3 1 (0.7)
G G C 7 1 (0.7)
IL6.0103
IL6.0104
IL6.0203
IL6.0204
IL6.0206
IL6.0207
IL6.0208
IL6.0209
IL6.0304
IL6.0307
IL6.0403
IL6.0407
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4.2. Allelotvpe and genotype of West of Scotland Gastric cancer patients
The genotype data observed from the West of Scotland gastric cancer patient population 
including H. Pylori status (where known) is shown in Table 5. This data is missing in 
some patients as these were diagnosed before it became standard routine practice to 
look for H. Pylori in the pathology slides. Table 6 contains the frequencies of the alleles 
and genotypes at the SNPs and 3' VNTR. Allele A at -594 was observed at 44.8% and G 
at 55.2%. Similarly at -172, the alleles were distributed at 48.5% and 50.5% (C and G 
respectively). At -570, allele C was very rare and seen only at 1.5% in comparison to 
98.5% for -570G.
Chi-squared analysis showed strong linkage disequilibrium between -594.A and -172.C, 
and -594.G and -172.G, (x2=68.9830, p<0.00001). No significant associations were 
observed at -570 and either of the alleles at -594 or -172.
In this population 4 haplotype families were observed, although the two prominent were 
IL6.01 and IL6.02, accounting for 95.5% of the total in this population. Tumour 
location bore no significance in the distribution. However, there was a significant 
difference when segregated regarding H.pylori status. The haplotype termed IL6.02 was 
observed more frequently in H.Pylori negative patients in comparison to positive 
patients where as haplotype IL6.01 was more common in positive patients, (x^=7.435, 
p=0.0243).
At the 3' region additional alleles were observed in comparison to the normal population 
and these can be observed in Table 6. Fig.5 demonstrates the overall range of alleles 
observed in the various West of Scotland cohorts. The results show that allele 3 was 
most frequently observed (48.1%) followed by allele 4 (25.0%) and allele 7 at 17.3%. 
Five prominent genotypes constituted 82.6% of the total observed. These were 3*3 
(26.9%), 3*7 and 3*4 (both at 19.2%), 4*4 (9.6%) and 4*7 (7.7%).
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TABLE 5
The results of the West of Scotland Gastric population
PATH. 5f 3* H.P.
NO. REGION REGION STATUS
FOK-I FNU4H-I NLA-III
-594 -570 -172
40001 GG GC GG nd nd
40003 GG GG CG nd nd
40005 GG nd CG nd nd
40006 AA GG CC 3*3 nd
40007 AG GG CG 3*7 nd
40008 nd GG nd nd nd
40009 nd nd nd 7*8 nd
40010 AA GG CC 3*3 positive
40011 GG GG GG 7*13 nd
40014 GG GG GG 3*7 nd
40016 AA GG CC nd nd
40018 AG GG CG nd positive
40020 AG GG CG 3*4 nd
40021 AG GG CC 3*7 nd
40022 AG GG CG 3*4 nd
40023 AG GG CG 3*6 nd
40024 GG GG GG 6*7 nd
40026 AG GG CG 3*3 nd
40027 GG GG GG nd negative
40028 GG GG GG nd nd
40029 AG GG CG 3*3 nd
40031 AG GG CC 3*7 negative
40032 AG GG CG 3*3 nd
40033 AA GG CC 3*3 positive
40035 AG GC CG 3*7 nd
40036 AG GG CG 3*7 nd
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PATH.
NO.
40038
40041
40043
40044
40045
40056
40058
40069
40071
40073
40075
40079
40085
40086
40091
40095
40096
40097
40100
40102
40123
40140
40147
40151
40153
40156
40161
40165
40170
FOK-I
REGION
FNU4H-I
-594 -570
AA GG
GG GG
AG GG
AG GG
GG GG
GG GG
AG GG
AA GG
GG GG
AA GG
AG GG
AA GG
AG GG
GG GG
GG GG
GG GG
AA GG
AG GG
AG GG
AA GG
GG GG
AG GG
AG GG
AG GG
AG GG
GG GG
GG GG
AA GG
AG GG
3’
REGION
NLA-III
-172
CC 3*3
GG 4*11
CG 3*4
CG 3*4
GG 4*7
GG nd
CG 3*4
CC 3*3
GG nd
CC 3*3
CG 3*7
CC nd
CG nd
GG nd
GG 7*8
GG 4*4
CC 3*3
CG 3*4
CG 4*4
CC 3*7
GG nd
CG 3*7
CG nd
CG 3*4
CG nd
GG 4*6
GG 4*4
CC 4*4
CG 3*4
PATH. 5’
NO. REGION
FOK-I FNU4H-I
-594 -570
40173 GG GG
40174 AA GG
40175 AA GG
40178 AA GG
40189 GG GG
40196 AG GG
40206 AG GG
40208 AA GG
40209 AG GG
40214 AG GG
40215 GG GG
40217 GG GG
40219 AG GG
40221 AG GG
3? H.P.
REGION STATUS
NLA-III
-172
GG 4*7 positive
CC 3*3 positive
CC 3*3 positive
CC 3*3 positive
CG 4*7 negative
CG 3*13 positive
CG 1*8 positive
CC 3*3 positive
CG 3*4 nd
CG 3*4 negative
GG 4*4 negative
GG 4*7 positive
CG nd positive
CG 3*7 negative
nd = not defined
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TABLE 6
Allele distribution at four polymorphic loci in the Gastric
West of Scotland population
ocus Allele Number Genotype Number
Observed (%) Observed (%)
■594 A 60 (44.7) A*A 15 (22.4)
G 74 (55.2) A*G 30 (44.8)
G*G 22 (32.8)
■570 C 2 (1.5) G*G 65 (97)
G 132 (98.5) G*C 2 (3)
C*C 0 (0)
•172 C 65 (48.5) C*G 17 (25.3)
G 69 (51.5) C*G 31 (46.3)
G*G 19 (28.4)
rVNTR 1 1 (0.9) 1*8 1 (1.9)
3 50 (48.1) 3*3 14 (26.9)
4 26 (25) 3*4 10 (19.2)
6 3 (2.9) 3*6 1 (1.9)
7 18(17.3) 3*7 10(19.2)
8 3 (2.9) 3*13 1 (1.9)
11 1 (0.9) 4*4 5 (9.6)
13 2 (1.9) 4*6 1 (1.9)
4*7 4 (7.7)
4*11 1 (1.9)
6*7 1 (1.9)
7*8 2 (3.8)
7*13 1 (1.9)
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FIGURE 5. Overall range of 3’alleles in a variety of West of Scotland cohorts
Five prominent genotypes constituted 82.6% of the total observed. These were 3*3 
(26.9%), 3*7 and 3*4 (both at 19.2%), 4*4 (9.6%) and 4*7 (7.7%).
Calculations showed associations across the promoter SNPs and 3' VNTR. 3' VNTR
allele 3 was significantly associated with -594.A and -172.C {%= 18.748, pc<0.000015,
2
X =34.9160, pc<0.00015). Similarly a strong association was also observed with -594.G
and -172.G with 3' allele 4 (-594.G: 3' allele 4, x"= 10.324, pc=0.0169, -172.G: 3’ allele
2
4, x =11.486, pc=0.0105). Additionally -594.G was also seen to be weakly associated 
with 3' allele 7 (x^=6.9180, p=0.0085) but which became insignificant when Bonferroni 
corrected (pc=0.1105). No significant association was observed with either of the -570 
alleles and the 3' VNTR.
As in the control population, the observed associations postulated that there were three 
potential relationships spanning the 5' SNP and 3' VNTR that showed haplotypic 
behaviour. These were IL6.0103, IL6.0204, and IL6.0207. The results verified these 
haplotypes. Of the 51 individuals tested, 11 were homozygous for IL6.0103 and 3 were 
homozygous IL6.0204. Genotyping further presented that 10 individuals were 
heterozygous IL6.0103/ IL6.0204, 5 individuals for IL6.0103/ IL6.0207 and 3 for 
IL6.0204/ IL6.0207. The haplotype IL6.0307 previously prominent in the West of 
Scotland control population occurred only once in this test population (0.9%). This is 
unlikely to be significant due to the small Gastric cohort and rarity of the C allele at - 
570. However, additional study is required to clarify this. Subtraction of these 
haplotypes revealed the remaining haplotypes, which can be observed with their 
frequencies in Table 7. It was observed that the three prominent haplotypes potentially 
accounted for 79.4% of the postulated haplotypes observed. There was no significant 
difference when these extended haplotypes were separated according to H.pylori status 
or tumour location.
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TABLE 7
Putative haplotypes observed in the West of Scotland Gastric
population
5' 3 f Number
594 -570 -172 VNTR observed (%)
A G C 1 1 (1) IL6.0101
A G c 3 46 (45.1) IL6.0103
A G c 4 3 (2.9) IL6.0104
A G c 7 1 (1) IL6.0107
G G G 4 23 (22.5) IL6.0204
G G G 3 4 (3.9) IL6.0203
G G G 6 3 (2.9) IL6.0206
G G G 7 12 (11.8) IL6.0207
G G G 8 2 (2) IL6.0208
G G G 11 1 (1) IL6.0211
G G G 9 2 (2) IL6.0213
G C G 7 1 (1) IL6.0307
G G C 7 3 (2.9) IL6.0407
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4.3. Barrett's Oesophagus patients
Analysis on patients diagnosed with Barrett's Oesophagus was carried out in two ways. 
Patients diagnosed with either the Benign or Malignant form of the disease were 
collectively grouped to produce a disease cohort for analysis against the West of 
Scotland control population and gastric cancer patients. The data were then categorised 
into the two sections to compare possible associations of the locus to malignancy in this 
disease.
Allelotvpe and genotype of West of Scotland Barrett's oesophagus 
patients
The combined data for the Barrett's Oesophagus patients with H. Pylori status are 
shown in Table 8, with their allele frequencies and their genotype counterparts in Table 
9. The results show that both -594.A and -172.C were less common than their 
counterpart -594.G and -172.G, at 39.8% and 40.1%. Allele C at -570 was very rare and
only seen 5.9%. Chi-squared analysis showed that -594.A and -172.C were in strong
2
linkage disequilibrium as were the corresponding -594.G and -172.G (x =116.368, 
p<0.00001). No other associations were observed amongst the 5' SNP.
Six putative haplotype families were represented in this population, five of which were 
identical to the control population. The sixth haplotype family absent in the control 
population and only detected once in this population was:
-594.A -570.C -172.C
Following the haplotype family nomenclature, this may be termed IL6.06. Consistent 
with the control population, the two prominent haplotype families in this group were 
IL6.01 and IL6.02, which accounted for 91.2%.
Separation of these haplotype families into H.pylori status revealed that there was a
2
significant difference in distribution of the two prominent haplotypes (x =12.111, 
p=0.0332). Haplotype family IL6.01 was more frequent in H.pylori negative patients, 
whilst IL6.02 was more frequent in positive patients.
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TABLE 8
The results of West of Scotland Barrett's Oesophagus population
BENIGN 5’
RRETT’S REGION
FOK-I FNU4-HI
Path No. -594 -570
7031/95 AG GG
7630/95 GG GG
7895/95 AG GC
8398/95 AA GG
8540/95 AA GG
8662/95 AG GG
9492/95 AA GC
9801/95 GG GG
10074/95 AG GG
10075/95 GG GG
10409/95 GG GG
10658/95 AA GG
10660/95 AA GG
11492/95 GG GG
11509/95 GG GG
12045/95 AG GC
12661/95 AG GG
12662/95 AG GG
12664/95 GG GG
13005/95 AG GG
13049/95 AA GG
13331/95 AG GG
1213/96 AG GG
1786/96 GG GG
3039/96 AG GC
3929/96 AA GG
3’ H.P.
VNTR STATUS
NLA-III
-172
CG 3*4 nd
GG 4*13 negative
CG 3*7 negative
CC 3*3 nd
CC 3*7 negative
CG 3*7 negative
CC 3*3 negative
GG 7*8 positive
CG 4*4 nd
GG 7*8 negative
GG 4*8 negative
CG nd negative
CC 3*3 negative
GG 4*7 nd
GG 4*4 nd
CG 3*7 nd
CG 4*4 nd
CG 3*7 nd
GG 6*7 positive
CG 5*7 negative
CC 3*3 nd
CG 3*4 positive
GG nd negative
CC 3*3 positive
CG 3*7 negative
CC nd nd
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ENIGN 5’ 3’ H.P.
lRRETT’S REGION VNTR STATUS
FOK-I FNU4-HI NLA-III
Path No. -594 -570 -172
5559/96 GG GG GG 4*7 positive
5596/96 GG GG GG 4*7 positive
6309/96 AG GG CG 3*3 negative
7942/96 AG GG nd 3*4 negative
7984/96 GG GG GG 4*4 positive
8486/96 AG GG CG 3*3 nd
10665/96 AG GG CG 3*4 negative
10686/96 AG GC CG 4*7 negative
10989/96 AA GG CC 3*3 negative
11552/96 AA GG CC 3*3 negative
14325/96 GG GG GG 3*4 negative
14600/96 AG GG CG 4*4 negative
14601/96 GG GG GG 4*7 negative
14645/96 AG GG CG 3*6 negative
14928/96 AG GG CG 3*4 negative
15274/96 AG GG CG 3*7 negative
1466/97 AA GG CC nd positive
1790/96 AA GG CC nd negative
2121/97 GG GG GG 6*7 negative
3126/97 AA GG CC nd negative
3485/97 GG GC GG 7*7 positive
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MALIGNANT 5’ 3’ H.P.
BARRETT’S REGION VNTR STATUS
FOK-I FNU4-HI NLA-III
-594 -570 -172
40004 AG GG CG 3*7 nd
40012 AG GG CG nd nd
40013 AG GG CC 3*7 nd
40015 GG GG GG nd nd
40017 GG GG GG 4*7 nd
40019 AG GG CG nd nd
40030 GG GG GG 4*7 nd
40037 GG GG GG 4*4 nd
40050 AA GG CC 3*3 positive
40051 AG GG CG 3*4 negative
40053 AG GG CG nd nd
40059 GG GC nd nd positive
40060 GG GG GG nd nd
40063 GG GG GG nd nd
40072 GG GC GG 7*8 negative
40074 AA GG CC 3*13 positive
40076 GG GG GG nd nd
40080 AA GG CC 4*4 positive
40094 nd nd GG nd nd
40098 GG GG GG 6*6 nd
40101 GG GG GG 7*13 nd
40105 GG GG GG nd nd
40106 nd nd CG nd positive
40112 AG GG CG nd negative
40118 AA GG CC 3*3 nd
40121 GG GG GG nd negative
40125 AG GG CG nd nd
40129 AG GG CG nd positive
40130 AG GG CG 3*4 positive
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MALIGNANT 5’ 3’ H.P.
BARRETT’S REGION VNTR STATUS
FOK-I FNU4-HI NLA-III
-594 -570 -172
40132 nd nd CG nd positive
40133 nd nd CG nd positive
40135 AG GG CG 3*7 nd
40142 AG GG GG nd nd
40144 nd nd CG nd positive
40146 GG GG GG nd positive
40158 GG GG GG 5*8 positive
40162 GG GG GG 4*8 negative
40163 GG GG GG 2*4 positive
40166 AG GC CG 3*7 negative
40180 GG GG GG 4*7 positive
40184 AG GG CG 3*6 negative
40187 AA GG CC nd nd
40193 AA GG CC 3*3 negative
40195 GG GG GG 4*7 negative
40199 AG GG CG 3*7 negative
40200 GG GG GG 4*7 positive
40201 GG GC GG 4*7 nd
40204 GG GG GG 4*4 positive
40205 GG GC GG 7*7 positive
40210 AG GG CG 3*8 nd
40211 AA GG CC 3*3 positive
nd = not defined
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TABLE 9
Allele distribution at four polymorphic loci in the Barrett?s 
Oesophagus population
Locus Allele Number Genotype Number
Observed (%) Observed
-594 A 74 (39.8) A*A 19 (20.4)
G 112(60.2) A*G 36 (38.7)
G*G 38 (40.8)
-570 G 175 (94.1) G*G 82 (88.2)
C 11 (5.9) G*C 11 (11.8)
C*C 0 (0)
-172 C 77 (40.1) C*C 20 (20.8)
G 115(59.9) C*G 37 (38.5)
G*G 39 (40.6)
3'VNTR 2 1 (0.7) 2*4 1 (1.4)
3 50 (35.2) 3*3 13(18.3)
4 39 (27.5) 3*4 8 (11.3)
5 2 (1.4) 3*6 2 (2.8)
6 6 (4.2) 3*7 12 (16.9)
7 34 (23.9) 3*8 1 (1.4)
8 7 (4.9) 3*13 1 (1.4)
13 3 (2.1) 4*4 8 (11.3)
4*7 11 (15.5)
4*8 2 (2.8)
4*13 1 (1.4)
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Genotype Number
Observed (%)
5*7 1 (1.4)
5*8 1 (1.4)
6*6 1 (1.4)
6*7 2 (2.8)
7*7 2 (2.8)
7*8 3 (4.2)
7*13 1 (1.4)
59
At the 3' region 3 prominent alleles were observed. These were allele 3 at 35.2%, 4 at 
27.5% and 7 at 23.9%. The most common genotypes observed were 3*3 (18.3%), 
followed by 3*7 and 4*7 (16.9% and 15.5% respectively). Analysis by Chi-square test 
revealed associations between 3' VNTR alleles and 5' SNP. Allele 3 was strongly
associated with -594.A and -172.C (x2=66.202, pc<0.00014, % = 73.030, pc<0.00014).
2
Alleles 4 and 7 were seen to be strongly associated with -594.G (x = 9.33, pc=0.0322, 
% -  8.906, pc=0.0392) and 172.G (%2=11.558, pc=0.0098, % = 8.576, pc=0.0476). 
Additionally -570.C was also strongly associated to 3' VNTR 7 (x2= 11.395,
2
pc=0.0084). Weak associations at allele 8 were observed with -594.G and -172.G % = 
5.734, p=0.0166, pc=0.2324, % = 6.144, p=0.0132, pc=0.1848. A weak association at 
allele 13 with -172.G (x2= 3.85, p=0.0497, pc=0.6958) completed all the observed 
associations.
A number of putative haplotypes were seen in the Barrett's Oesophagus patients 
although, as in the control population, the four prominent were IL6.0103, IL6.0204, 
IL6.0207, and IL6.0307. From the population 8 were homozygous for IL6.0103 and 3 
showed IL6.0204 homozygosity. Additionally, genotyping revealed heterozygosity in 3 
individuals for the haplotypes IL6.0103/ IL6.0207, 5 for IL6.0204/ IL6.0207 and 2 for 
IL6.0103/ IL6.0204. In total these 4 prominent haplotypes represented 76.4% of the 
total population and the remaining can be observed in Table 10.
In comparison to the haplotype families, segregation of extended haplotypes according 
to H. pylori infection detected no significant difference in the distribution. This was 
further confirmed by Monte Carlo simulation.
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Table 10
Putative haplotvpes observed in the West of Scotland Barrettfs
Oesophagus population
5f 3* Number
594 -570 -172 VNTR o b serv ed  (% )
A G C 3 43 (30.7) IL6.0103
A G c 4 6 (4.3) IL6.0104
A G c 5 1 (0.7) IL6.0105
A G c 7 1 (0.7) IL6.0107
A G c 13 1 (0.7) IL6.0113
G G G 2 1 (0.7) IL6.0202
G G G 3 3 (2.1) IL6.0203
G G G 4 32 (22.9) IL6.0204
G G G 5 1 (0.7) IL6.0205
G G G 6 6 (4.3) IL6.0206
G G G 7 23 (16.4) IL6.0207
G G G 8 7 (5) IL6.0208
G G G 13 2 (1.4) IL6.0213
G C G 7 9 (6.4) IL6.0307
G G C 3 3 (2.1) IL6.0403
G G C 7 1 (0.7) IL6.0407
A C c 3 1 (0.7) IL6.0603
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Allelotvpe and genotype of West of Scotland Benign Barretts patients
The 5' SNP allelotype and counterpart genotypes can be observed in Table 11. At 
position -594, allele G and -172.G were observed at 53.2% and 53.3% compared to the 
less common alleles at 46.8% and 46.7%. In contrast allele G at -570 was most common 
at 93.6%.
Probability analysis showed significant association between -594.A and -172.C 
(y l  =49.695s pco.00001) as there was for -594.G and -172.G. Chi-squared analysis 
showed no further significant association with either alleles at -570 and those at -594 or 
-172.
Six putative haplotype families were represented in this population. However the two 
haplotype families, which also showed significant association, were IL6.01 and IL6.02 
accounting for 89.1%. When these haplotypes families were classed in relation to 
H.pylori infection, a significant difference in the distribution was detected. Haplotype 
family IL6.01 was more frequent in H.pylori negative patients compared to infected 
individuals, who had a higher distribution of IL6.02.
Of the 7 alleles present at the 3' region, alleles 3, 4 and 7 were the most common (39%, 
28% and 23.2% respectively) making up 90.2% of the total. The most common 
genotypes were 3*3 (21.6%), 3*7 (17.1%) and 3*4 (14.6%). Analysis by chi-square 
showed that the 5' SNP were significantly associated with alleles in the 3' region. - 
594.A and -172.A were significantly associated with allele 3 (x2=28.117, pc<0.00012,
% =32.993, pc<0.00012 respectively). Additionally, allele G at -594 was weakly 
associated with 3' VNTR alleles 4, 7 and 8 (allele 4, x2=5.328, p=0.021, pc=0.252, 
allele 7, % = 3.990, p=0.0458, pc=0.5496, allele 8, x2=4.194, p=0.0416, pc=0.4992 
respectively) as was allele G at -172 (allele 4, x2=6.613, p=0.0101, pc=0.1212, allele 7, 
% = 4.586, p=0.0322, pc=0.3864, allele 8, %=4311, p=0.0354, pc=0.4248 respectively).
The associations and data obtained showed that there were five potential relationships 
across the polymorphic region, which behaved as putative haplotypes. These were 
similar
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TABLE 11
Allele distribution at four polymorphic loci in the Benign Barrett’s
population
Locus Allele Number Genotype Number
Observed (%) Observed
•594 A 44 (46.8) A*A 12 (25.5)
G 50 (53.2) A*G 20 (42.6)
G*G 15(31.9)
•570 G 88 (93.6) G*G 41 (87.2)
C 6 (6.4) G*C 6 (12.8)
C*C 0 (0)
■172 C 43 (46.7) C*C 12 (26)
G 49 (53.3) C*G 19(41.3)
G*G 15 (32.6)
J'VNTR 3 32 (39) 3*3 9 (21.6)
4 23 (28) 3*4 6 (14.6)
5 1 (1.2) 3*6 1 (2.4)
6 3 (3.7) 3*7 7 (17.1)
7 19 (23.2) 4*4 5 (12.2)
8 3 (3.7) 4*7 5 (12.2)
13 1 (1.2) 4*8 1 (2.4)
4*13 1 (2.4)
5*7 1 (2.4)
6*7 2 (4.9)
7*7 1 (2.4)
7*8 2 (4.9)
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to the prominent haplotypes observed in the West of Scotland control population, i.e. 
IL6.0103, IL6.0204, IL6.0207, and IL6.0307. In this population however, IL6.0208 was 
detected to be a prominent putative haplotype. Data from the population indicated that 5 
individuals were homozygous for IL6.0103, 1 for homozygous IL6.0204 and 4 for 
heterozygous IL6.0103/ IL6.0204. Additionally, 3 were heterozygous for IL6.0103/ 
IL6.0307, 3 for heterozygous IL6.0103/ IL6.0307 and 3 for heterozygous IL6.0204/ 
IL6.0207. The four prominent haplotypes were seen to potentially account for 76.3% of 
the postulated haplotypes. Extraction of these haplotypes revealed the rest, which can 
be observed in Table 12.
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TABLE 12
Putative haplotypes observed in the West of Scotland Benign Barrett’s
population
5’ 3f N um ber
594 -570 -172 VNTR observed  (% )
A G C 3 25 (31.3) IL6.0103
A G c 4 4 (5) IL6.0104
A G c 5 1 (1.3) IL6.0105
A G c 7 1 (1.3) IL6.0107
G G G 3 3 (3.8) IL6.0203
G G G 4 18 (22.5) IL6.0204
G G G 6 3 (3.8) IL6.0206
G G G 7 13 (16.3) IL6.0207
G G G 8 3 (3.8) 1L6.0208
G G G 13 1 (1.3) IL6.0213
G C G 7 5 (6.3) IL6.0307
G G C 3 2 (2.5) IL6.0403
A C C 3 1 (1.3) IL6.0603
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Allelotvpe and genotype of West of Scotland Barrett's malignant 
patients
The data observed for malignant Barrett's patients can be observed in Table 13. A 
smaller proportion of the allele A at -594 and C at -172 was observed (32.6% and 34%). 
At -570, allele G was observed 94.6%. Analysis detected strong linkage disequilibrium
between the two G alleles and alleles A and C, both at -594 and -172 respectively
2
(X =64.8, p<0.00001), but no association with alleles at -570 and either of the alleles at 
-594 o r -172.
The accumulation of obtained results and analysed data determined five haplotype 
families, although the two prominent were IL6.01 and IL6.02 accounting for 93.3%. In 
this study the distribution of the haplotypes according to H.pylori infection showed no 
significance. This data was also analysed against previous data obtained by H. Kasem 
whom showed the haplotype a2d4 at the TNF was significantly associated to this 
disease. There was no significant distribution of any observed haplotype family to the 
microsatellite alleles TNF a2 or d4, or the genotype a2d4. However there was a 
significant difference of the two prominent haplotype families IL6.01 and IL6.02, and 
alleles TNF a6 (x2=6.414, p=0.0113, % =6.520, p=0.0107 respectively) and
d3(x2=24.528, p<0.00001, x2=21.179, p<0.00001). Furthermore this distribution
2 2 
difference was detected against the genotype TNF a6d3 (x =3.861, p=0.0494, x =5.642,
p=0.0175).
At the 3' region 3 alleles were prominent; allele 3 (30%), allele 4 (26.7%) and allele 7 
(25%). The most common genotypes observed were 4*7 (20%), 3*7 (16.6%) and 3*3 
(13.3%). Chi-squared analysis showed associations between the 5' SNP and the three 
common allele at the 3' VNTR. A strong association was observed with -594. A and 
-172.C with allele 3 (x2 =40.179, pc<0.00013, % =41.368, pc<0.00013 respectively). At 
allele 4 and 7 only weak associations which became insignificant when Bonferroni 
corrected were observed with both -594.G and -172.G (at allele 4: -594.G, % =4.176, 
p=0.041, pc=0.533, -172.G, % =65.065, p=0.0244, pc=0.3172, at allele 7: -594.G: x2 
=5,
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TABLE 13
Allele distribution at four polymorphic loci in the Malignant Barrett’s
population
Locus Allele Number Genotype Number
Observed (%) Observed (%)
-594 A 30 (32.6) A*A 7 (15.2)
G 62 (67.4) A*G 16 (34.8)
G*G 23 (50)
-570 G 87 (94.6) G*G 41 (89.1)
C 5 (5.4) G*C 5 (10.8)
C*C 0 (0)
-172 C 34 (34) C*C 8 (16)
G 66 (66) C*G 18 (38)
G*G 24 (48)
3'VNTR 2 1 (1.6) 2*4 1 (3.3)
3 18 (30) 3*3 4 (13.3)
4 16(26.7) 3*4 2 (6.6)
5 1 (1.6) 3*6 1 (3.3)
6 3 (5) 3*7 5 (16.6)
7 15 (25) 3*8 1 (3.3)
8 4 (6.7) 3*13 1 (3.3)
13 2 (3.3) 4*4 3 (10)
4*7 6 (20)
4*8 1 (3.3)
5*8 1 (3.3)
6*6 1 (3.3)
7*7 1 (3.3)
7*8 1 (3.3)
7*13 1 (3.3)
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p=0.0253, pc=0.3289, -172.G: % =3.956, p=0.0467, pc=0.6071). Additionally -570.C
2
was also weakly associated with allele 7 (% =6.4291, p=0.0112, pc=0.1344).
As in the West of Scotland control population, these associations and supported data 
suggested that there were four prominent extended haplotypes in this cohort. These 
were IL6.0103, IL6.0204, IL6.0207 and IL6.0307. From the population, 4 individuals 
were homozygous for IL6.0103 and 2 for IL6.0204. Additionally, 2 individuals were 
heterozygous for IL6.0103/ IL6.0207, 5 for IL6.0204/ IL6.0207, 1 individual for 
IL6.0103/ IL6.0307 and 1 for IL6.0204/ IL6.0307. Extraction of the putative haplotypes 
revealed the remaining in this population and is represented in Table 14. Separation of 
the haplotypes in relation to H.pylori status or tumour location presented no 
significance in the haplotype distribution.
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TABLE 14
Putative haplotypes observed in the West of Scotland Malignant
Barrett1 s population
5T 3f Number
594 -570 -172 VNTR observed  (% )
A G C 3 18 (30) 1L6.0103
A G c 4 2 (3.3) IL6.0104
A G c 13 1 (1.7) IL6.0113
G G G 2 1 (1.7) IL6.0202
G G G 4 14 (23.3) IL6.0204
G G G 5 1 (1.7) IL6.0205
G G G 6 3 (5) IL6.0206
G G G 7 10 (16.7) IL6.0207
G G G 8 4 (6.7) IL6.0208
G G G 13 1 (1.7) IL6.0213
G C G 7 4 (6.7) IL6.0307
G G C 7 1 (1.7) IL6.0403
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4.4. Allelotype and genotype of an African American control
population
The data for the African American control population and the Rheumatoid arthritis 
patients at the 5'SNPs were obtained by Osiri et al and have since been published 
(1999). The data is also presented in Table 15, which also include the 3' VNTR. The 
allelotypes and genotypes at each locus are in Table 16. Osiri et co observed unequal 
distribution of alleles. At -594, allele G was most common and present 94.3%, as was 
allele G at -172 and allele G at -570 (91.5% and 95.3% respectively).
2
Two by two contingency tables and x analysis showed that -594.A was significantly
2
associated to -172.C (x =11.643, p=0.0006). No association was observed with either of 
the -570 alleles and the other SNP's.
They reported 5 haplotype families from their data, which they termed one to five 
according to their observed frequency. These were:
-594.G -570.G -172.G
-594.G -570.C -172.G
-594.A -570.G -172.C
-594.A -570.G -172.G
-594.G -570.G -172.C
These were identical to those detected in the West of Scotland control population, 
although the distribution differed. In this population, IL6.02 was most common, 
followed by IL6.03, IL6.01,116.05, and 116.04. This thesis further developed on the 5’ 
SNP data and analysed the 3' VNTR and their corresponding associations.
Analysis at the 3' region showed that additional alleles were present in comparison to 
those observed in the West of Scotland population. A nomenclature was thus designed 
to maintain the original numbers allocated in the Caucasian cohort, but distinguish the 
new alleles by adding a suffix 'S' or 'L', characterising a 'shorter' or 'longer' allele, to the 
allele number located closest. For example, an allele positioned slightly above allele 6 
on the gel was identified as 6L identifying this allele to be longer than 6. Six new alleles
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TABLE 15
The results of the African American control population
SAMPLE 5’
NO.
FOK-1
REGION
FNU4H-I NLA-III
-594 -570 -172
118 GG GG GG
119 GG GG GG
120 GG GG GG
121 GG GG GG
122 GG GG GG
123 GG GG GG
124 GG GG GG
125 GG CG GG
126 GG CC GG
127 GG GG GG
128 GG GG GG
129 GG CC GG
130 GG GG GG
131 GG GG GG
132 GG GG GG
133 GG GG GG
134 GG GG GG
135 GG GG GG
136 GG GG GG
137 GG GG GG
138 GG GG GG
139 GG CG GG
140 GG GG GG
3?
VNTR
nd
3*6
7*8
6*7
7*7
nd
4*13
7*7
nd
nd
4*13
6*6
6*6
nd
4*7
7*11
6*6
6*6
4*6
7*7
7*13
7*7
3*7
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SAMPLE
NO.
141
142
143
144
145
146
147
149
150
151
152
153
154
155
156
157
158
159
160 
161 
162
163
164
165
166
167
168
FOK-1
-594
GG
GG
AG
GG
AG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
AG
GG
GG
AG
GG
GG
AG
GG
GG
GG
AG
5'
REGION
FNU4H-I
-570
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
CG
GG
GG
GG
GG
CG
GG
GG
GG
GG
GG
CG
NLA-III
-172
GG
GG
GC
GG
GC
GG
GG
GC
GG
GG
GG
GC
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GG
GC
3’
VNTR
4*10
7*7
3*3
3*6
3*7
6*7
nd
3*3
3*3
6*13
7*10L
3*6
6*13
6*7
6*13
6L*7L
10*13
3*9
4*7
3*6
7*7
6*7
3*4
nd
2*7
4*7
3*7
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SAMPLE
NO.
FOK-1
-594
169 GG
170 GG
171 GG
REGION
FNU4H-I NLA-III
-570 -172
GG GG
GG GG
GG GG
3'
VNTR
3*7
7*8
10*13
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TABLE 16
Allele distribution at four polymorphic loci in the African American
control population
Locus Allele Number 
Observed (%
Genotype Number 
Observed (%
■594 A 6 (5.7) A*A 0 (0)
G 100 (94.3) A*G 6 (8.5)
G*G 47 (88.7)
■570 G 97 (91.5) G*G 46 (86.8)
C 9 (8.5) G*C 5 (9.4)
C*C 2 (3.8)
172 C 5 (4.7) C*C 0 (0)
G 101 (95.3) C*G 5 (9.4)
G*G 48 (90.6)
I'VNTR 2 1 (1) 2*7 1
3 16(17) 3*3 3
4 8 (8.5) 3*4 1
6 20 (21.3) 3*6 4
6L 1 (1) 3*7 4
7 29 (29) 3*9 1
7L 1 (1) 4*6 1
8 2 (2.1) 4*7 3
9 1 (1) 4*10 1
10 3 (3.2) 4*13 2
10L 1 (1) 6*6 4
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Allele Number Genotype Number
Observed (%) Observed (%)
11 1 (1) 6*7 4
13 8 (8.5) 6* 13 3
6L*7L 1
7*7 6
7*8 2
7*10L 1
7*11 1
7*13 1
10*13 2
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were detected in the individuals of African American background in relation to 
Caucasians from the West of Scotland, three of which were presented in the African 
American control population. These represented (3.2%) of the total observed alleles. 
These are presented in fig.6. Allele 7 was seen most frequent in this population (33%), 
followed by allele 6 (21.3%) and allele 3 (17%). No genotype was seen to prevail above 
any other. Analysis of the 3' VNTR only showed two weak associations to the 5' SNPs. 
This was with allele 3 where by a weak association was observed with -594. A and - 
172.C (x=8.392, p=0.038, pc=0.722, x=6.434, p=0.0112, pc=0.1792.
The detected associations postulated that there was one potential extended relationship 
between 5' SNP and 3' VNTR:
-594.A -570.G -172.C 3 'VNTR.3
The data however suggested another two putative haplotypes prominent in this cohort:
-594.G -570.G -172.G 3 'VNTR.7
-594.G -570.G -172.G 3 'VNTR.6
Consistent with the proposed nomenclature for the haplotypes in the West of Scotland 
control population, these can therefore be termed IL6.0103, IL6.0207, and IL6.0206 
respectively. From the data, 3 individuals were homozygous for the haplotypes 
IL6.0207, 3 for IL6.0206 and 1 individual for IL6.0103. Additionally, 4 were 
heterozygous for IL6.0206/ IL6.0207, 2 for IL6.0103/ IL6.0206, and 1 individual for 
IL6.0103/ IL6.0207.
These putative haplotypes potentially accounted for 54.4% of the total haplotypes. 
Subtraction of these haplotypes revealed the additional haplotypes. However, there were 
a few indeterminate data that did not contain one of the prominent extended haplotypes. 
These data could not be conclusively categorised as there were potentially two different 
haplotype combinations. For this thesis, it was suggested that the probable haplotype 
combination more frequently observed in the African American population were most 
probable and therefore added to the total of extended haplotypes.
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Lane 1: 6S / 7 
Lane 2: 6S / 7 
Lane 3 : 7S / 7 
Lane 4: 3 / 6L 
Lane 5: 7 / 10
Lane 1 : 6 / 8  
Lane 2: 6S / 6S 
Lane 3: 6S / 6S 
Lane 4: 4 / 10L 
Lane 5: 7 / 10
Lane 1 : 3 / 7  
Lane 2: 7L / 13 
Lane 3: 6 / 13 
Lane 4: 4 / 13L 
Lane 5: 4 /  13
FIGURE 6. A demonstration of additional alleles in the African- 
American Population
Table 17 shows the total of both the concluded putative haplotypes, which disregard the 
few data, and the suggested potential haplotypes for these data. Further analysis of the 
haplotype distribution with other cohorts was examined with both sets of results. 
However, the presence or absence of the suggested haplotypes did not alter the outcome 
of the comparative analysis with other cohorts.
78
Table 17
Putative haplotypes observed in the African American control
population
5f 3f Number
-594 -570 -172 VNTR observed (%)
A G C 3 3(3.7) IL6.0103
G G G 2 1 (1.2) IL6.0202
G G G 3 9(11) IL6.0203
G G G 4 7 (8.5) IL6.0204
G G G 6 16 (19.5) IL6.0206
G G G 7 26 (31.2) IL6.0207
G G G 7L 0(0) IL6.027L
G G G 8 2 (2.4) IL6.0208
G G G 9 1 (1.2) IL6.0209
G G G 10 2 (2.4) IL6.0210
G G G 10L 1 (1.2) IL6.0210L
G G G 11 1(1.2) IL6.0211
G G G 13 7 (8.5) IL6.0213
G C G 6 2 (2.4) IL6.0306
G C G 6L 0(0) IL6.0306L
G C G 7 3 (3.7) IL6.0307
G G C 3 1 (1.2) IL6.0403
A G G 3 0(0) IL6.0603
G G C 10 0(0) IL6.0610
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4.5. Allelotype and genotype of Rheumatoid arthritis patients in
African Americans
The data observed for the rheumatoid arthritis patients can be observed in Table 18 and 
the allelotypes and genotypes at each locus are in Table 19. The data for the 5' promoter 
SNPs were obtained by Osiri and co workers. They observed that the alleles of the 5' 
SNP's were unequally distributed. At -594, -570 and -172 the G alleles were the most
common and present 94.9, 90.2% and 93.5% respectively. Two by two contingency
2
tables and x analysis showed that -594.A and -172.C were in linkage disequilibrium to 
each other, as were -594.G and -172.G (x2=105.847, p<0.00001). No association was 
observed with either of the -570 alleles and the other SNP's.
From this data, they identified 4 haplotype families that were present in the control 
population. The fifth haplotype family, -594.G, -570.G, -172.C, present in the controls 
was absent in this population.
The data of the 3' VNTR revealed allele 7 was most frequent in this population (28.4%), 
followed by allele 6 (23.6%) and allele 3 (11.5%). No genotype was prominent. 
Analysis of the 3' allele 3 showed strong associations to allele A at -594 and allele C at - 
172 (x 2=75.834, pc<0.00023, x2=55.331, pc=0.00025). Weak associations were also
observed with allele 6 and allele 7 at -594.G and -172.G (x2=5.318, p=0.0211,
2
pc=0.4853, x =7.344, p=0.0067, pc=0.1675). No associations were observed with either 
of the allele at -570.
Based upon the associations observed and the allele distribution it was postulated that 
the four putative haplotypes detected were the same as those in the African American 
population. The data showed 9 individuals were homozygous for IL6.0207, 6 for 
IL6.0206, 1 individual for IL6.0103 and one for IL6.0203. Additionally, 10 were 
heterozygous for IL6.0203/ IL6.0207, 2 for IL6.0203/ IL6.0206, and 1 for IL6.0206/ 
IL6.0207. These putative haplotypes potentially accounted for 61.8% of the total 
haplotypes. Subtraction of these haplotypes revealed additional haplotypes and 
remaining data was calculated as before.
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TABLE 18 
The results of the African American Rheumatoid arthritis population
SAMPLE 5’ 3f
NO. REGION REGIO
FOK-I FNU4-HI NLA-III
-594 -570 -172
1 GG CG GG 7*7
2 GG GG GG 3*1
3 GG GG GG 7L*13
4 GG GG GG 4*1
5 GG GG GG 6*13
6 GG GG GG 6*6
7 GG GG GG 4*13L
8 GG CG GG 4*13
9 GG GG GG 6*6
10 GG CG GG 8*8
11 AG GG GC 4*7
12 GG CG GG 4*7
13 GG CC GG 7*13
14 GG GG GG 13*13
15 GG GG GG 7*10
16 GG GG GG 4*7
17 GG GG GG 3*3
18 GG CG GG 6*9
19 GG GG GG 13*13
20 GG GG GG 4*7
21 GG GG GG 6*7
22 AG GG GC 3*4
23 GG GG GG 7S*7
24 GG CG GG 3*6L
26 GG GG GG 7*7
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SAMPLE
NO.
28
FOK-I
-594
GG
29 GG
30 GG
31 GG
32 GG
33 GG
35 GG
36 GG
37 GG
38 AG
40 GG
41 GG
42 GG
43 GG
44 GG
45 GG
47 GG
48 GG
49 GG
50 GG
51 GG
52 AG
53 GG
54 GG
55 GG
56 GG
57 GG
58 AG
59 GG
5f
REGION
FNU4-HI NLA-III
-570 -172
CG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GC
GG GG
GG GG
CG GG
GG GG
CG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GC
CG GG
GG GG
GG GG
GG GG
GG GG
GG GC
CG GG
3f
REGION
6S*7
6*13
6S*8
6*10
7*7
6*7
6*13
4*7S
4*7
3*13
6*6
6S*13
nd
6S*6
3*7
4*6
7*10L
6*7
6*10L
1*6
6*6
4*9
6*6
5*9
6*7
6*7
4*6
3*3
nd
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SAMPLE
NO.
60
FOK-I
-594
GG
61 AG
62 AG
63 GG
65 GG
67 GG
69 AG
70 GG
71 GG
72 AA
73 GG
74 GG
15 GG
76 GG
77 GG
78 GG
79 GG
80 GG
81 GG
82 GG
83 GG
84 GG
85 GG
86 GG
87 GG
88 GG
89 GG
90 AG
91 GG
5’
REGION
FNU4-HI NLA-III
-570 -172
GG GG
GG GC
GG GC
GG GC
GG GG
GG GG
GG GC
GG GG
GG GG
GG CC
GG GG
GG GG
GG GG
CG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
GG GG
CG GG
GG GG
GG GG
GG GC
GG GG
3f
REGION
7*7
3*3
3*6
3*6
3*4
7*13
3*3
3*10
3*6
3*3
4*10L
4*6
6*13
6*10
2*7
7*7
7*7
nd
nd
6*7
6*7
7*7
6S*13
4*7
6*7
6*6
7*13
3*13
6*8
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SAMPLE
NO.
92
FOK-I
-594
GG
93 GG
94 GG
95 GG
96 GG
97 GG
98 GG
99 GG
100 GG
101 GG
102 GG
103 GG
104 GG
105 GG
106 GG
107 GG
108 GG
109 GG
110 GG
111 GG
112 GG
113 GG
114 GG
115 GG
116 GG
117 GG
5’
REGION
FNU4-HI NLA-III
-570 -172
GG GG
CG GG
CG GG
GG GG
GG GG
GG GG
GG GG
CG GG
GG GG
GG GG
GG GG
GG GG
GG GC
GG GG
GG GG
CC GG
GG GC
GG GG
GG GG
GG GG
GG GG
GG GG
CG GG
GG GG
GG GG
GG GG
3f
REGION
6*8
4*7
7*7
7*10
6*6
6*10L
6*7
6*13
3*7
6*7
nd
7*7
4*10L
6*7
7*13
6*7
7*13
6*8
6S*6S
7*7
7*7
3*6
7*7
6*7
6S*13
3*4
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TABLE 19 
Allele distribution at four polymorphic loci in the African American 
Rheumatoid arthritis patients
Locus Allele Number Genotype Number
Observed (%) Observed
-594 A 11 (5.1) A*A 1 (0.9)
G 205 (94.9) A*G 9 (8.3)
G*G 98 (90.7)
-570 G 195 (90.3) G*G 89 (82.4)
C 21 (9.7) G*C 17(15.7)
C*C 2 (1.9)
-172 C 14 (6.5) C*C 1 (0.9)
G 202 (93.5) C*G 12(11.1)
G*G 95 (88)
3'VNTR 1
2
3
4
5
6S
6
6L
7S
7
1 (0.5)
1 (0.5) 
24(11.5) 
20 (9.6)
1 (0.5)
8 (3.8) 
49 (23.6)
1 (0.5)
2 (1)
59 (28.4)
Genotype
1*6
2*7
3*3
3*4
3*6
3*6L
3*7
3*10
3*13
4*6
Number
Observed(%)
1
1
5
3
4 
1 
3 
1 
2 
3
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Genotype Number
Observed (%)
7L 1 (0.5) 4*7S 1
8 6 (2.9) 4*7 8
9 3 (1.4) 4*9 1
10 5 (2.4) 4*10L 2
10L 5 (2.4) 4*13 1
13 21 (10.1) 4*13L 1
13L 1 (0.5) 5*9 1
6S*6S 1
6S*6 1
6S*7 1
6S*8 1
6S*13 3
6*6 7
6*7 13
6*8 3
6*9 1
6*10 2
6*10L 2
6*13 5
7S*7 1
7*7 12
7*10 2
7*10L 1
7*13 5
7L*13 1
8*8 1
13*13 2
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The total of extended haplotypes and those including the suggested haplotypes can be 
observed in table 20, The addition or extraction of the predicted putative haplotypes did 
not alter the overall analysis. Neither did their presence or absence affect further 
comparative analysis.
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TABLE 20 
Putative haplotypes observed in the African American Rheumatoid
arthritis population
Number 
observed (%)
5f 3f
-594 -570 -172 VNT]
A G C 3
A G c 4
A G c 9
G G G 1
G G G 2
G G G 3
G G G 4
G G G 5
G G G 6S
G G G 6
G G G 7S
G G G 7
G G G 7L
G G G 8
G G G 9
G G G 10
G G G 10L
G G G 13
G G G 13L
G C G 3
G C G 4
G C G 6S
G C G 6
G C G 6L
G C G 7
G C G 8
9 (5.1) IL6.0103
0 (0) IL6.0104
0 (0) IL6.0109
1 (0.001) IL6.0201
1 (0.001) IL6.0202
12 (6.7) IL6.0203
14 (7.9) IL6.0204
1 (0.001) IL6.0205
7 (3.4) IL6.0206S
42 (23.6) IL6.0206
2 (0.01) IL6.0207S
47 (26.4) IL6.0207
1 (0.001) IL6.027L
5 (2.8) IL6.0208
1 (0.001) IL6.0209
4 (2.2) IL6.0210
4 (2.2) IL6.0210L
17 (9.6) IL6.0213
1 (0.001) IL6.0213L
0 (0) IL6.0303
0 (0) IL6.0304
0 (0) IL6.0306S
2 (0.01) IL6.0306
0 (0) IL6.0306L
5 (2.8) IL6.0307
1 (0.001) IL6.0308
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-594 -570 -172 VNTR
G C G 6
G c G 10
G c G 13
G G C 3
G G C 10L
G G C 13
Number 
observed (%)
0 (0) IL6.0309
0 (0) IL6.0310
1 (0.01) IL6.0313
0 (0) IL6.0403
0 (0) IL6.0410L
0 (0) IL6.0413
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4.6. Comparison of populations
Gastric Carcinoma cohort versus Normal control West of Scotland population
Chi-squared analysis has shown that although there were slight differences between 
gastric allelotypes and genotypes at the 5' SNP region, no significant association was 
observed. Additionally this was also true at the 3' VNTR region where by although 
additional alleles were observed, there were too few to present significance or affect the 
rest of the distribution (table 6). For the sample size in this comparison, the power to 
detect an odds ratio (OR) of 2 was greater than 0.9 at both -174 and -594. However, at 
-570, the low frequency of the C allele reduced the power to 0.53.
The distribution of the haplotype families in gastric cancer patients presented a similar 
pattern to the controls and thus showed no significance by chi-square analysis. Power 
analysis was carried out on all haplotypes that were observed at a frequency of greater 
than 10%. In these, the power to detect an OR of 2 was at least 0.79.
The same strong associations spanning the 5’ SNP and 3' VNTR in the normal 
population were seen in the gastric population at -594 and -172 and 3' VNTR alleles 3 
and 4. However at allele 7 the alleles at -172 were not associated. Additionally, neither 
alleles at -570 were associated with any 3' VNTR alleles. This however bore no 
significance to the distribution of haplotypes. This was confirmed by the Monte carlo 
simulation analysis.
Barrett’s Oesophagus cohort versus Normal control West of Scotland population
No statistical difference was observed between these two groups, neither with the 
allelotypes or genotypes at the 5' SNP region. Despite the presence of additional alleles 
at the 3 ’ VNTR, there was no significance difference in the distribution. Consequently, 
haplotype families and extended haplotypes showed no significant distributionAs 
observed with the gastric cohort, the power to detect an OR of 2 was greater than 0.9 for 
-172 and -594 and 0.66 for -570. Haplotype analysis also identified a power of greater 
than 0.79 to detect an OR of 2.
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When the Barrett's Oesophagus cohort was split according to malignancy diagnosis, i.e. 
Benign and Malignant Barrett's, there was no significant difference at the 5’ SNPs and 
thus also in the haplotype family distribution. However, comparison at the 3’ VNTR 
revealed that the genotype 3*4 was slightly less frequent in the Malignant Barrett's 
cohort in comparison to the West of Scotland cohort (x2=4.972, p=0.0258, pc=0.7482). 
Yet this bore no significance when comparing the extended haplotypes of the malignant 
patients in comparison to the control individuals. Power analysis on all haplotypes with 
a frequency of greater than 10% showed a power of at least 0.89 at an OR of 2.
Gastric Carcinoma cohort versus Barrett's Oesophagus cohort
Analysis on allelotype distribution showed a significant difference between Barrett's
Oesophagus patients and Gastric Carcinoma patients at -570. The former group had a
2
higher frequency of the rare allele C in comparison to the Gastric cohort (x =3.907, 
p=0.0481). However, no other significant difference was observed at the 5' SNPs or 3' 
VNTR.
The absence of significant difference was further demonstrated in the distribution of the 
5’ haplotype families. A significant difference was observed when the 3’VNTR alleles 
were added to form the extended haplotypes and a higher frequency of IL6.0307 was 
detected in Barrett's Oesophagus patients (x2=4.084, p=0.0433, pc>0.9999) in 
comparison to the Gastric cohort. Furthermore, IL6.0103 was slightly more frequent in 
Barrett's Oesophagus (x2=5.251, p=0.0219, pc=0.5475)
Gastric Carcinoma cohort versus Malignant Barrett’s cohort
A significant distribution was detected at -172 between the gastric carcinoma cohort
and malignant Barrett's Oesophagus population. Allele G was significantly more
2
frequent in Malignant Barrett's compared to Gastric carcinomas (x =4.398, p=0.0263), 
where patients showed an almost equal distribution of the two alleles. Consistent with
this observation, the haplotype families containing allele C at -172 were significantly
2
less frequent in Malignant Barrett's compared to Gastric Carcinomas (% =4.602, 
p=0.0319).
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Additionally, at the 3' VNTR allele 3 was slightly less frequent in Malignant Barrett's
2
(X =5.123, p=0.0236), which disappeared with Bonferroni correction (pc= 0.3776). This 
insignificance was further demonstrated with no significant genotype distributions.
H.Pvlori status in Gastric carcinoma cohort versus Barrett’s Oesophagus cohort
H.Pylori segregation in Barrett’s Oesophagus and Gastric carcinoma displayed a 
significant reversal in the distribution of haplotype families IL6.01 and IL6.02. In
H.Pylori positive patients, the distribution of the haplotype family IL6.02 was
2
significantly more frequent m Barrett's Oesophagus patients (x =11.107, p=0.0112), 
whilst in Gastric patients, a higher frequency of IL6.01 was observed.
Similarly, in patients whom H.pylori was absent, the distribution was again
significantly reversed with the haplotype family IL6.02 significantly lower in Barrett's
2
Oesophagus patients in comparison to Gastric patients (x =12.279, p=0.0311).
H.Pvlori status in Gastric carcinoma cohort versus Malignant Barrett’s cohort
H.Pylori status again presented a role in the distribution of haplotypes in the analysis of
the gastric carcinoma cohort and Malignant Barrett’s cohort. IL6.02 was significantly
more frequent in the Malignant Barrett's Oesophagus patients whom were H.Pylori
2
positive in comparison to the Gastric cohort (x =4.635, p=0.0313).
Differences between the two cohorts was also demonstrated when combining the 3’
VNTR, whereby the extended haplotype IL6.0307 was slightly more frequent in the
2
Malignant Barrett's Oesophagus cohort (x =4.421, p=0.0355) in comparison to the 
Gastric cohort. Bonferroni correction diminished this slight significance (pc>0.9999)
Malignant Barrett’s cohort versus Benign Barrett's cohort
Comparison of the two Barrett’s cohorts detected a significant decrease of allele A at 
-594 in Malignant Barrett's in comparison to Benign Barrett's, whom showed a similar 
distribution of the two alleles. This significance however was not extended to the 
genotypes.
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There was no significant distribution of the haplotype families between the two cohorts 
or due to H.pylori status. This was further demonstrated in similar distribution of the 
extended haplotypes.
African American Rheumatoid arthritis cohort versus African American control 
population
Data analysis determined that there was no significant difference in the distribution of 
allelotypes and genotypes both at the 5' SNPs and 3' VNTR. This lack of significance 
was further observed in the distribution of haplotype families. Although additional 
associations spanning across the locus were detected in the rheumatoid arthritis patients, 
this bore no significance in the distribution of the extended haplotypes. Power analysis 
for alleotypes and haplotypes demonstrated a power of at least 0.98 for an OR of 2, 
except for allele at -570 where the rarity of allele C decreased the power to 0.65.
African American control populations versus West of Scotland control populations
When analysing the two ethnically different cohorts, significant differences were 
observed. The distribution of alleles at -594 and -172 were significantly different in
these cohorts (x2=43.835, pO.OOOOl, %=51.553, p<0.00001 respectively). These
2
differences were further portrayed in the distribution of genotypes (-594, x =44.071, 
pcO.OOOOl, - 172, x 2=50.742, pO.OOOOl).
The significant differences were further demonstrated in the comparison of extended 
haplotypes. In the African Americans, a higher distribution of haplotypes IL6.0206, 
IL6.0207, and IL6.0213 were detected in relation to the West of Scotland population 
(IL6.0206 x2 =16.842, pO.OOOOl, pc0.00031, IL6.0207 x2=5.921, p=0.015, 
pc=0.0465, IL6.0213 % =13.137, p=0.0003, pc=0.0093). Additionally IL6.0203 was
slightly more frequent (x2=7.039, p=0.008, pc=0.248). In comparison, haplotype
2
IL6.0103 was significantly increased in the West of Scotland population (x =41.508,
pc<0.00031). These significant distributions correlate with the observation that a higher
frequency of the haplotype family IL6.01 was detected in the West of Scotland
2
population and IL6.02 in the African American cohort respectively (x =55.621, 
p<0.00001, pc<0.00004).
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DISCUSSION
In this study, the distribution of four polymorphic elements spanning across the locus of 
IL-6 in the West of Scotland were investigated and their relationship analysed by the 
chi-square test. This provided data to determine putative haplotype families in the 
promoter region and extended haplotypes encompassing the 3* VNTR. Once these 
putative haplotypes were established in the control population, additional disease 
populations were examined in order to determine variations. Investigation of an African 
American cohort and subsequent rheumatoid individuals provided a comparison of the 
putative haplotypes in a different ethnic group and its association with an autoimmune 
disease.
5.1. Control population analysis
In order to show variations of polymorphisms in disease patients, control populations 
are needed as comparable standards. Therefore, the West of Scotland and the African 
American control populations were primarily investigated.
The distribution observed in the West of Scotland population at the -172 polymorphism 
is analogous to that recently described for Caucasians by Fishman et al [1997]. Allele C 
was observed at 44.2% in this study in comparison to the 40.3% in Fishman's 
population. Faulds et al [accession num ber AF048692] described a similar distribution 
of the -594 polymorphism, with allele A at 43.2% in relation to our 41.7%. The 
polymorphism at -570 has not previously been described in Caucasians. In our 
population, allele C at -570 was sparsely distributed at 4.5%, with the G allele being 
much the more common, at 95.5%.
In the African American population, the polymorphisms at the 5' SNPs have not 
previously been reported. However, these can be compared to the West of Scotland 
population to show any ethnic variations. A significantly higher frequency of the G 
alleles at both -594 and -172 were observed in the African American population (94.3% 
and 91.5% respectively). However at -570, allele C was similarly sparsely distributed in 
both populations (West of Scotland, 4.5% and African Americans, 8.5%). In these 
populations, the sparseness of allele C suggests that it is barely polymorphic enough to
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be of interest in its own right in these populations, although as later shown, it was of 
importance in defining the haplotypes.
The frequency of these markers has also been detected in different ethnic origins with 
varying distribution frequencies. At -172, Fishman et al have shown allele G to be 
present at 86% and 95.5% in Gujarati Indians and Afro-Caribbean's respectively. The 
latter cohort shows a similar distribution to that of the African American population 
studied here. Additionally, the rare allele C at -570 in the West of Scotland and African 
American population has been observed to be prominent in a recent study in Japanese 
women (82%) [Nakajima et al, 1999]. The differences in ethnic variations such as these 
are both common and expected, thus highlighting that a significant observation in one 
ethnic population may not always be of relevance or detected in another. Furthermore it 
emphasises the importance of presenting results with correct control populations.
Associations within the 5* locus of the West of Scotland population illustrated that the 
-594.A allele was in strong linkage disequilibrium with -172.C and that -594.G allele 
was similarly linked to the corresponding -172.G allele. In general, both these 
combinations were found with the common -570.G allele. However, it was observed 
that the rare -570.C allele was only found with -594.G and -172.G allele, suggesting it 
has arisen against this background.
These associations proposed that there were three combinations of 5' SNPs in the 
promoter. Subtraction from the data revealed a further two rare combinations, 
suggesting there were 5 haplotype families in the West of Scotland population:
-594.A -570.G -172.C
-594.G -570.G -172.G
-594.G -570.C -172.G
-594.G -570.G -172.C
-594.A -570.G -172.G
I have proposed that these haplotype families be termed IL6.01, IL6.02, IL6.03, IL6.04 
and IL6.05.
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In the African American population, the G alleles at -594 and -172 were also seen in 
linkage disequilibrium, as were their counterparts. Additionally, as in the West of 
Scotland, the rare allele C at -570 was only found with -594 and -172 G alleles. The 
associations and data revealed the same haplotype families and these have recently been 
published [Osiri et al, 1999]. However in this population the distribution was altered. 
Haplotype family IL6.02 was the most common, as it was for the West of Scotland 
cohort, although at a higher incidence (African American population, 84.1%, West of 
Scotland, 51.4%) followed by IL6.03 and IL6.01. The marked difference in distribution 
therefore reflects the ethnic disparity between the two cohorts.
The 3' variable number tandem region (VNTR) of IL-6 was originally described by 
Bowcock et al [1988] who observed 4 alleles although mentioned that additional alleles 
may be present due to the likelihood of unresovable microheterogeneity resulting from 
the low-resolution the agarose gel separation. In this study a total 13 irregularly spaced 
alleles were observed in a variety of control and patient groups from the West of 
Scotland Caucasians. In the control West of Scotland cohort, 7 were represented 
although three dominated the population; alleles 3, 4 and 7 (42.1%, 31.5%, and 20.2% 
respectively). These observations contrast with those of Murray et al [1997], who used 
an ABI machine to detect only 2 dominant alleles from a total of 6 conserved in their 
Caucasian control population.
In the African American population, an additional 6 alleles were observed, four of 
which were detected in the control panel. In order to retain the nomenclature allocated 
in the West of Scotland population, the new alleles were allocated a suffix S or L to 
determine a 'shorter' or 'longer' allele than the original. In this population, alleles 6 and 7 
were the most common (23.6% and 28.4%). The distribution differences of the two 
cohorts again reflect the varieties detected in ethnic cohorts.
Associations between the alleles at the 5' SNP's and 3' VNTR suggested there were four 
potential relationships which integrate the alleles within the IL-6 locus in the West of 
Scotland population. The associations within these groups were such that it was 
proposed they behave as haplotypes:
96
-594.A -570.G -172.C 3' VNTR 3
-594.G -570.G -172.G 3’ VNTR 4 (-570.G by default)
-594.G -570.G -172.G 3' VNTR 7 (-570.G by default)
-594.G -570.C -172.G 3' VNTR 7
These haplotypes were thus termed IL-6.0103, IL-6.0204, IL-6.0207 and IL-6.0307 
respectively. The first part of the terminology is from their respective frequencies 
observed in this population and the latter part of the terminology makes use of the 3' 
VNTR to further differentiate one haplotype from another. These haplotypes potentially 
accounted for 87% of the genotypes observed. Subtraction of these haplotypes from the 
data in table 2 further revealed the seven remaining proposed haplotypes shown in table 
4. However these were too infrequent to be proposed as prominent.
The distribution of the remaining IL-6 3’ VNTR against the 5’ combinations in the 
other individuals was then examined. Only two individuals showed any variation on the 
putative IL6.0103 haplotype, having allele 4 on the IL6.01 background:
-594.A -570.G -172.C 3’VNTR 4
No other 3' alleles appeared on the IL6.01 background, suggesting that the proposed 
haplotype IL6.0103 is either recent, or contains undefined elements which inhibits or 
prevents change. It may also suggest that, like the strongly conserved B8-DR3 
haplotype and its associated TNF locus alleles in Caucasians, it is under selection 
pressure to remain stable [Gallagher et al, 1997]. The stability of this haplotype is 
further emphasised by the recent study by Fishman et al [1998] on a polymorphic 
[A]n[T]m tract in the promoter region, lying between the -570.G/C and -172G/C site in 
the IL-6 promoter. Although considerable independent variation was observed in the 'A' 
and T  runs, they detected only one individual showing variation when -172.C allele 
was present and all the remaining variants were in association with the -172.G allele. 
This further emphasizes the stability of the IL6.0103 haplotype. However, genotyping 
this locus using a recently described method would conclusively resolve this question 
[Tschentscher et al, 2000].
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Fishman et al [1998] also demonstrated that the -172.C allele was significantly less 
frequent in S-JCA patients and that promoter constructs containing this allele were less 
transcriptionally active following stimulation by LPS. This was reflected in normal 
individuals who were homozygous for this allele and had lower serum IL-6 levels, in 
comparison to those whom carried the -172.G. This project demonstrates that this 
marker is in strong linkage disequilibrium with two other promoter alleles and one 3 * 
allele. Therefore, it can be postulated that one or more of these additional alleles can 
contribute to the association of -172 allele with IL-6 secretion. Similarly, Linker-Israeli 
et al [1999] have demonstrated an association between the 3’VNTR region of the IL-6 
gene and SLE. However, there may be additional SLE-related alleles involved in the 
dysregulation of IL-6 secretion.
In the African American population, strong associations at VNTR allele 3 were 
detected with -594.A and -172.C. This therefore suggests that these polymorphic loci 
may behave as the haplotype:
-594.A -570.G -172.C 3’VNTR 3
This haplotype termed IL-6.0103, as in the West of Scotland population, showed no 
variation at the 3' VNTR against the IL6.01 background, thus again suggesting 
undefined elements inhibiting its modification. However it was also only observed in 3 
individuals (3.7%) thus suggesting that it is a strongly conserved recessive haplotype. 
Alternatively, it may also suggest that this haplotype is of a Caucasian origin and its 
presence in the African American population may have arisen due to ethnic mixing.
The data revealed an additional 3 prominent relationships, which may suggest 
haplotypic behaviour:
-594.G -570.G -172.G 3' VNTR 7
-594.G -570.G -172.G 3' VNTR 6
-594.G -570.G -172.G 3' VNTR 3
These relationships do not show any statistical associations other than the linkage 
disequilibrium at the -594 and -172 sites. This may be because there are so many other
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alleles at the 3' VNTR against the common haplotype background any statistical 
significance would be reduced. Yet their frequency observed may suggest that there are 
selection factors influencing the gene to incline towards these extended alleles.
5.2. Gastric carcinoma analysis
Analysis of the four polymorphic elements in the gastric carcinoma cohort revealed 
similar distributions to those of the normal cohort. At the 3' region, although 2 
additional alleles were detected, neither the distribution nor further analysis was altered. 
It is unlikely that the appearance of these additional alleles in this cohort are gastric 
cancer related, but probably due to the increased chance of detecting the rarer alleles 
with increasing sample numbers analysed. The statistical data revealed the same 
haplotypic families and extended associations as those of the normal cohort. Previous 
published data has indicated that levels of serum IL-6 correlate markedly with disease 
status in gastric cancer [Wu et al, 1996] and that IL-6 is an autocrine growth factor for 
some gastric cancer cell-lines [Ito et al, 1997]. Therefore a genetic determinant in IL-6 
is of importance in gastric carcinoma. Disappointingly however, a major conclusion 
from this study is that the 4 polymorphisms analysed in this study are not the genetic 
markers that relate to this disease.
When the gastric cohort was analysed with respect to H.pylori status, a significant 
difference was detected with the 5' alleles. The 5' haplotype IL6.02 was significantly 
more frequent in H.pylori negative patients in comparison to the prevalent IL6.01 in 
H.pylori positive patients. An early study has shown that infected H.pylori dyspeptic 
patients have increased IL-6 levels [Gionchetti et al, 1994]. Therefore, it can be 
postulated that the 5' haplotype IL-6.02 may control IL-6 levels, which in turn may 
provide a protective role against H.pylori associated gastritis. However, further study 
relating the plasma levels of IL-6 in H.pylori associated gastric cancer patients and the 
haplotypic phenotypes would be required for clarification. A recent study that may 
possibly challenge our data is that of Fishman et al, (1998) who have shown that 
increased plasma IL-6 levels correlate with the presence of -172G. This would imply 
that IL6-02, the haplotype containing the allele -172.G, would be expected to be 
significantly associated with H.pylori positive patients. Therefore, from our data, it 
could be assumed that high plasma IL-6 levels are not favourable to H.pylori in gastric
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carcinoma, and may be limiting its growth. However, the levels of IL-6 correlating with 
-172.G have only been observed in rheumatoid arthritis patients. A similar study in 
patients with inflammatory bowel disease found no significant difference of IL-6 
production in relation to -172 alleles [Koss et al, 1999]. Therefore, it could also be 
postulated that this is an event related only to autoimmune diseases. A similar study in a 
gastric cancer cohort, as suggested above, is required to resolve this question. 
Furthermore, our data is unfortunately based on a limited cohort, as H.Pylori status was 
not known in the entire patient cohort as explained earlier. A larger study would be 
beneficial to provide a clearer picture.
Extending the haplotypes to include the 3' minisatellites eliminated the significant 
result, suggesting the 3' allele has no genetic role in this gastric cohort. Additionally, 
analysing the cohort in relation to tumour location also showed no significant 
difference.
5.3 Barrett's Oesophagus analysis
The Barrett's Oesophagus cohort included patients diagnosed with the Benign or 
Malignant form. Analyses were carried out on the combined cohort and then when 
segregated with respect to their diagnosis.
In this cohort, a new 5' haplotype family was observed and hence termed IL6.06 
following the nomenclature pattern. However, it was only detected once and bore no 
significance in further statistical analysis in comparison to the normal cohort. Similarly, 
additional 3' alleles were detected, but again these did not affect the distribution or 
further analysis. Therefore our data concluded that the 4 polymorphisms investigated 
singularly and as haplotypic families in a collective cohort of Barrett's Oesophagus 
patients were not statistically different to the normal population.
Segregation of the cohort according to H.pylori status revealed no significant 
differences. However, when the patients were categorised according to diagnosis and 
H.pylori status is again reviewed, a significant difference between the positive H.pylori 
Benign population and the negative H.pylori Benign population was detected. As in the 
gastric cancer cohort, a difference was detected in the distribution of the two prominent
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haplotype families IL6.01 and IL6.02. The data revealed that haplotype family IL6.01 
was more frequent in H.pylori negative patients, whilst IL6.02 was more frequent in 
positive patients. This is in contrast to the gastric cohort, whom showed IL6.01 
prevalent in H.pylori positive patients. H.pylori does not play a significant role in 
Barrett's Oesophagus as the stomach bacterium is not found in the oesophageal region. 
Hence, it is can be assumed that the possible protective role of IL6.02 against H.pylori 
would not be of importance. Further investigation as to the relevance of the significant 
distribution to IL-6.02 would address the role of this haplotype family in H.pylori and 
Barrett’s Oesophagus patients.
A recent study by H.Kasem [1999] has shown that the haplotype a2d4 in the TNF is 
significantly associated to Barrett's Oesophagus. However our data concluded that there 
were no IL-6 haplotype families associated with this genotype, therefore concluding 
that these polymorphisms are not associated with disease. Analysis of other TNF 
polymorphisms indicated that a significant difference between the two prominent 
haplotype families IL6.01 and IL6.02, and the two alleles TNF a6 and d3, and the 
genotype TNF a6d3 in the malignant cohort. The function of the TNF alleles is not 
known, but it is clear that there is a strong link between the TNF genotype and IL6 
haplotypes. Therefore any future study on markers in one cytokine should be with 
consideration to the other as it is possible all the polymorphisms are contributing to the 
effect.
Comparison of the Barrett's cohort in relation to the gastric cohort revealed a slight 
difference in the frequency of IL6.0307 and IL6.0103. However these differences are 
likely to be due to sample numbers as in the gastric cohort allele C at -570 was only 
observed twice, and Bonferroni correction diminishes the significance. A larger study 
would be assist in clarifying this observation
5.4 Rheumatoid arthritis analysis
Data analysis determined that there was no significant difference in the distribution of 
allelotypes and genotypes both at the 5' SNPs and 3' VNTR between the two African 
American cohorts. In the rheumatoid arthritis patients additional associations spanning 
across the locus were detected, but these did not affect the overall distribution of 
haplotype families. The recent by Fishman et al (1997) showed that the C allele at -172
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correlates with lower IL-6 levels and S-JCA patients have the CC genotype significantly 
less frequently. However, in this cohort the alleles at -172 were not significantly 
different in their distribution. This can be explained by the ethnic variations. As stated 
earlier, the allele G at -172 has been investigated in various ethnic populations 
providing different frequencies. It is very possible therefore, that different factors affect 
the production of IL-6, as previous studies suggest [Hulkkone et al, 2001, Collado- 
Escobar, 2000]. Furthermore, it is possible that additional genetic markers will be acting 
against the result of -172 allele in the normal cohort where as this effect is 'switched off 
in arthritic patients.
5.5 Experimental analysis
The methods applied for this thesis were quick, easy and effective. Amplification 
followed by complete digestion for the 5' polymorphisms give indisputable results. The 
only consideration required was to digest for the appropriate length of time. Incomplete 
digestion was possible with a short time span, whereas overnight digestion could 
potentially cause false cleaving. This was especially true for digestion with Fok-I as this 
enzyme was able to construct a complimentary nucleotide to a sequence allowing 
potential random cleaving between any two nucleotides. Therefore preliminary studies 
deemed 3 hours to be appropriate. Known standards showing the three digestion results 
were also added for each run to ensure complete and accurate digestion. Analysis of 3' 
VNTR region by denaturation PAGE was a more superior method to that previously 
carried out by Bowcock et al [1988] whom showed 4 alleles. The PAGE gels provided 
higher resolution, thus overcoming the unresovable heterogeneity encountered by the 
agarose gel separation. This enabled the additional alleles that Bowcock referred to be 
observed with more clarity. Yet still even this separation system is not totally accurate 
and it is felt there may be additional alleles not seen. This is based upon the difficulty in 
calling samples that look slightly variable in density upon the gels. The variation may 
be due to slight differences in the gel consistency or alternatively may be due to single 
base pair additions/deletions. From the procedures available at the moment, additional 
sequencing of samples that are ambiguous would clarify this. Yet this is not practical 
due to the expense, and it would lead to an additional complication relating as to the 
number of base addition/deletion/substitutions that would warrant a new allele.
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CONCLUSION AND FUTURE STUDIES
To conclude, this study investigated 4 polymorphic elements spanning across the locus 
of IL-6 and analysed their relationship with each other. In the West of Scotland control 
population, the 3 polymorphisms in the 5' region showed strong linkage disequilibrium 
and hence these associations indicated that there were three common combinations. 
Further analysis revealed two rare combinations concluding that there are the following 
5' haplotype families in this cohort:
-594.A -570.G -172.C
-594.G -570.G -172.G
-594.G -570.C -172.G
-594.G -570.G -172.C
-594.A -570.G -172.G
By observing the common practice of naming haplotype families, these are termed 
IL6.01, IL6.02, IL6.03, IL6.04 and IL6.05.
Further analysis of the 3' region minisatellite using PAGE overcame the unresovable 
heterogeneity encountered by Bowcock et al (1989) and enabled us to observe a total of 
13 irregularly spaced alleles in a variety of control and patient groups from the West of 
Scotland Caucasians, 7 of which were represented in the control cohort. Statistical 
analysis revealed further associations with the minisatellite alleles, thus suggesting 4 
putative extended haplotypes, which integrate the alleles within the IL-6 locus:
■594.A -570.G -172.C
594.G -570.G -172.G
594.G -570.G -172.G
594.G -570.C -172.G
3' VNTR 3
3' VNTR 4 (-570-1 1 by default)
3* VNTR 6 (-570-1 1 by default)
3' VNTR 6
These haplotypes were thus termed IL6.0103, IL6.0204, IL6.0207 and IL6.0307 where 
the latter part of the terminology makes use of the 3' VNTR and further differentiates 
one haplotype from another.
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The results obtained therefore suggest that the genetic polymorphisms in the promoter 
region cannot be considered independent from one another, but instead be remembered 
that other markers may be contributing to the overall observed effect. It would have 
been interesting to develop this and study the expression of IL-6 by the different 
haplotype families. This could be then compared in different cohorts in order to 
determine the effect of haplotype families and resulting IL-6 expression, in relation to 
patient groups. However, since the completion of this study, Terry et al (2000) have 
indeed looked at functional effect of 4 polymorphisms in IL-6. Three of these were the 
5' promoter SNP's that were studied here, and the fourth being the AnTn track at -373. 
They identified their natural occurring haplotypes and compared their effects on 
reporter gene expression. The data revealed that different transcriptional regulation 
occurred in the ECV304 cell in comparison to the HeLa cell, thus suggesting that the 
haplotypes have cell-type specific regulation. Additionally, the haplotypes showed 
different transcriptional rates in the ECV 304 cell line, thus correlating with our 
hypothesis that the polymorphisms do not act independently but that other markers 
influence the overall functional effect.
Analysis of these haplotypes in a gastric carcinoma cohort revealed no statistical 
difference in the haplotype families or extended haplotypes in comparison to the control 
population. Similarly, analysis in the Barrett's Oesophagus patients either segregated 
according to diagnosis or combined, also showed a similar distribution to the control 
cohort. However, the presence of H.pylori significantly affected the frequency of the 
two prominent haplotype families, IL6.01 and IL6.02 in both cohorts. The gastric cohort 
revealed that the 5' haplotype IL6.01 was significantly more frequent in H.pylori 
positive patients. Yet in contrast, H.pylori positive Barrett's Oesophagus patients had a 
significantly higher frequency of the haplotype IL6.02. The inclusion of the 3' VNTR in 
the statistical analysis however, diminished the significance suggesting that in the 
patient cohorts, the minisatellite alleles only play a minor role. Additionally tumour 
location in the gastric cohort showed no statistical difference in haplotype frequencies.
Gene expression of the haplotype families would be of great advantage in these cohorts 
as there are clearly haplotype family preferences when observed in relation to H.pylori 
status. It would be of interest then to note if a haplotype family which may have
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increased 11-6 production, may play a specific role in H.pylori associated gastritis or 
Barrett's Oesophagus.
Analyses of an African American cohort revealed the same haplotype families, but were 
shown in different frequencies; IL6.02 was the most common, followed by IL6.03 and 
IL6.01. In this ethnic population, an additional 6 minisatellite alleles were observed, 
four of which were detected in the control panel. Comparison to a rheumatoid arthritic 
cohort indicated no significant difference in the distribution of allelotypes, genotypes 
and subsequent haplotypes suggesting that the polymorphisms do not have an important 
role in disease susceptibility.
Since completion of this study, a recent group has also observed that there is no 
difference of the polymorphisms -594 and -172 between rheumatoid arthritic patients 
and comparative control. However they stressed that the polymorphisms may contribute 
to the pathogenesis of the disease by influencing the age of onset of RA [Pascual et al, 
2000].
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